package com.gcgenome.lims.interpretable.impl

import com.gcgenome.lims.JsonConfig
import com.gcgenome.lims.constants.Clazz
import com.gcgenome.lims.dto.Disease
import com.gcgenome.lims.dto.InterpretationPanel
import com.gcgenome.lims.dto.ParameterPanel
import com.gcgenome.lims.entity.Request
import com.gcgenome.lims.inserts.*
import io.mockk.every
import io.mockk.mockkClass
import org.junit.jupiter.api.DisplayName
import org.junit.jupiter.api.Test
import org.springframework.data.elasticsearch.core.document.Document
import reactor.core.publisher.Mono
import kotlin.test.BeforeTest

internal class SingleTest{
    private val om = JsonConfig().objectMapper()
    private val requestDao = mockkClass(RequestDao::class)
    private val snvDao = mockkClass(SnvDao::class)
    private val insertList = listOf(`(S030,S032)PreSuffix`(), N046PostSuffix(), N048PostSuffix(), N055PostSuffix(), N122Negative(), N122PostSuffix(),
        GenePlusNegativeDefault(), RareDiseaseNegativeDefault(), SingleGeneNegativeDefault())
    private val interpreter = Single(om, requestDao, snvDao, insertList)

    @BeforeTest
    fun initMock(){
        // testPositiveS032
        every { requestDao.findById(202203231715095, "S032") }.returns(
            Mono.just(
                Request(
                sample = 202203231715095, service = "S032",
                organization = "L014011", organizationName = "사회복지법인한국혈우재단",
                sampleType = "WB", patientName = "정리*", sex = "F"
            )
            )
        )
        every { snvDao.find("22GMD029", "01db4ff4-9689-47b0-b0d9-1659788912c5:22GMD029:029:hg19:X:138630520:A:T") }
            .returns(Mono.just(Document.parse(PV1)))
        // testPositiveTP53
        every { requestDao.findById(202206159144401, "X009") }.returns(
            Mono.just(
                Request(
                sample = 202206159144401, service = "X009",
                organization = "L014011", organizationName = "부천순천향(개인)",
                sampleType = "WB", patientName = "서가윤", sex = "F"
            )
            )
        )
        every { snvDao.find("22BRCA027", "a118c948-74b9-4929-abf9-35d8a50e6f37:22BRCA027:008:hg19:17:007577081:T:G") }
            .returns(Mono.just(Document.parse(LPV1)))

        // testNegativeS065
        every { requestDao.findById(202105251715184, "S065") }.returns(
            Mono.just(
                Request(
                sample = 202105251715184, service = "S065",
                organization = "L014011", organizationName = "대구가톨릭대학교의료원",
                sampleType = "WB", patientName = "강성현", sex = "M"
            )
            )
        )
        every { requestDao.findById(202208011715110, "S030") }.returns(
            Mono.just(Request(sample = 202208011715110, service = "S030", organization = "L014011", organizationName = "대구가톨릭대학교의료원", sampleType = "WB", patientName = "강성현", sex = "F"))
        )
        every { requestDao.findById(202109011715037, "S061") }.returns(
            Mono.just(Request(sample = 202109011715037, service = "S061", organization = "L014011", organizationName = "대구가톨릭대학교의료원", sampleType = "WB", patientName = "강성현", sex = "F"))
        )
        every { snvDao.find("21GMD048", "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022:hg19:13:052548140:A:C") }
            .returns(Mono.just(Document.parse(BV1)))
        every { snvDao.find("21GMD048", "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022:hg19:13:052544805:C:G") }
            .returns(Mono.just(Document.parse(BV2)))
        every { snvDao.find("21GMD048", "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022:hg19:13:052524488:T:C") }
            .returns(Mono.just(Document.parse(BV3)))
        every { snvDao.find("21GMD048", "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022:hg19:13:052523808:C:T") }
            .returns(Mono.just(Document.parse(BV4)))
        every { snvDao.find("21GMD048", "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022:hg19:13:052515354:A:G") }
            .returns(Mono.just(Document.parse(BV5)))
        every { snvDao.find("21GMD048", "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022:hg19:13:052511606:G:A") }
            .returns(Mono.just(Document.parse(BV6)))
        // testPositiveS061
        every { requestDao.findById(202106221715329, "S061") }.returns(
            Mono.just(
                Request(
                sample = 202106221715329, service = "S061",
                organization = "L014011", organizationName = "대구가톨릭대학교의료원",
                sampleType = "WB", patientName = "최지은", sex = "F"
            )
            )
        )
        every { snvDao.find("21Cancer058", "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003:hg19:11:064577381:G:GGGGCT") }
            .returns(Mono.just(Document.parse(S061LPV1)))
        every { snvDao.find("21Cancer058", "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003:hg19:11:064572602:G:A") }
            .returns(Mono.just(Document.parse(S061BV1)))
        every { snvDao.find("21Cancer058", "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003:hg19:11:064572557:A:G") }
            .returns(Mono.just(Document.parse(S061BV2)))
        every { snvDao.find("21Cancer058", "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003:hg19:11:064572018:T:C") }
            .returns(Mono.just(Document.parse(S061BV3)))
        every { snvDao.find("22AN003", "01db4ff4-9689-47b0-b0d9-1659788912c5:22AN003:007:hg19:13:113803609:C:G")}
            .returns(Mono.just(Document.parse(S030NEGATIVEADD)))
        every { snvDao.find("21Cancer083", "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004:hg19:11:064574565:G:T")}
            .returns(Mono.just(Document.parse(S061POSITIVE)))
        every { snvDao.find("21Cancer083", "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004:hg19:11:108213957:CCT:C")}
            .returns(Mono.just(Document.parse(S061POSITIVEADD)))
    }

    @Test
    @DisplayName("Panel Positive S032")
    fun testPositiveS032(){
        val param = ParameterPanel(
            ParameterPanel.Sex.M,
            InterpretationPanel.builder().apply {
                appendVariant(
                    InterpretationPanel.Variant(
                        gene = "F9",
                        clazz = Clazz.PV,
                        hgvsc = "c.392-2A>T",
                        hgvsp = "p.?",
                        disease = "HB",
                        zygosity = "Het",
                        inheritance = "XL",
                        snv = "hg19:X:138630520:A:T",
                        analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:22GMD029:029",
                        diseaseFullName = null,
                        interpretation = null,
                        genPhenDb = null
                    )
                )
            }.build()
            , mapOf(
                "F9" to listOf(Disease("Hemophilia B", "HB", listOf("XL")))
            ), "test suffix")
        val value = interpreter.interpret(202203231715095, "S032", param).block()
        println(om.writeValueAsString(value))
        kotlin.test.assertEquals(
            InterpretationPanel(
                "POSITIVE",
                "PV가 발견되었습니다.",
                "R/O Hemophilia B",
                null,
                "NM_000133.4(F9)",
                "HB, Hemophilia B",
                "Het, Heterozygous; XL, X-linked; PV, Pathogenic Variant",
                "F9 유전자에서 Pathogenic Variant (PV)가 발견되었습니다.\n\nF9 유전자의 c.392-2A>T (p.?) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이입니다. 이 변이는 기존에 F9-related disease 환자에서 보고된 바 있습니다(PMID: 10090477).\n\nF9 유전자는 HB 관련 유전자로 XL 유전 양상을 보입니다.\n\n- Mature protein:\n- Reported severity:\n- History of inhibitor:\n- Reference ID:\n- Year reported:\n\ntest suffix",
                null,
                null,
                listOf(
                    InterpretationPanel.Variant(
                        gene = "F9",
                        clazz = Clazz.PV,
                        hgvsc = "c.392-2A>T",
                        hgvsp = "p.?",
                        disease = "HB",
                        zygosity = "Het",
                        inheritance = "XL",
                        snv = "hg19:X:138630520:A:T",
                        analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:22GMD029:029",
                        diseaseFullName = "Hemophilia B",
                        interpretation = null,
                        genPhenDb = null
                    )
                ),
                null,
                null,
                null
            ),
            value
        )
    }


    @Test
    @DisplayName("Panel Positive X009")
    fun testPositiveX009(){
        val param = ParameterPanel(
            ParameterPanel.Sex.M,
            InterpretationPanel.builder().apply {
                appendVariant(
                    InterpretationPanel.Variant(
                        gene = "TP53",
                        clazz = Clazz.LPV,
                        hgvsc = "c.857A>C",
                        hgvsp = "p.Glu286Ala",
                        disease = "LFS",
                        zygosity = "Het",
                        inheritance = "AD",
                        snv = "hg19:17:007577081:T:G",
                        analysis = "a118c948-74b9-4929-abf9-35d8a50e6f37:22BRCA027:008",
                        diseaseFullName = null,
                        interpretation = null,
                        genPhenDb = null
                    )
                )
            }.build()
            , mapOf(
                "TP53" to listOf(Disease("Li-Fraumeni syndrome", "LFS", listOf("AD")))
            ), null)
        val value = interpreter.interpret(202206159144401, "X009", param).block()
        println(om.writeValueAsString(value))
        kotlin.test.assertEquals(
            om.readValue("{\"result\":\"POSITIVE\",\"result_text\":\"LPV가 발견되었습니다.\",\"reason_for_referral\":null,\"clinical_information\":null,\"abbreviation_reference\":\"NM_000546.5(TP53)\",\"abbreviation_disease\":\"LFS, Li-Fraumeni syndrome\",\"abbreviation\":\"Het, Heterozygous; AD, Autosomal dominant; LPV, Likely Pathogenic Variant\",\"interpretation\":\"TP53 유전자에서 Likely Pathogenic Variant (LPV)가 발견되었습니다.\\n\\nTP53 유전자의 c.857A>C (p.Glu286Ala) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이로, in-silico prediction(SIFT, MutationTaster)에서는 Deleterious로 예측되었습니다. 이 변이는 기존에 보고된 바 있으며(PMID: 1569604), ClinVar에서 LPV로 분류되어 있습니다(ID: 376593).\\n\\nTP53 유전자는 LFS 관련 유전자로 AD 유전 양상을 보입니다.\",\"mean_depth\":null,\"coverage\":null,\"variants\":[{\"snv\":\"hg19:17:007577081:T:G\",\"analysis\":\"a118c948-74b9-4929-abf9-35d8a50e6f37:22BRCA027:008\",\"gene\":\"TP53\",\"hgvsc\":\"c.857A>C\",\"hgvsp\":\"p.Glu286Ala\",\"zygosity\":\"Het\",\"disease\":\"LFS\",\"disease_full_name\":\"Li-Fraumeni syndrome\",\"inheritance\":\"AD\",\"class\":\"LPV\"}],\"recommendation\":null,\"addendum\":null,\"incidental_findings\":null,\"authors\":[],\"revision\":false}", InterpretationPanel::class.java),
            value
        )
    }

    @Test
    @DisplayName("Panel Negative S065")
    fun testNegativeS065(){
        val param = ParameterPanel(
            ParameterPanel.Sex.M,
            InterpretationPanel.builder().apply {
                appendVariant(InterpretationPanel.Variant(gene = "ATP7B", clazz = Clazz.BV, hgvsc = "c.1216T>G", hgvsp = "p.Ser406Ala", disease = "WD", zygosity = "Hom", inheritance = "AR", snv = "hg19:13:052548140:A:C", analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022", diseaseFullName = null, interpretation = null, genPhenDb = null)); appendVariant(
                InterpretationPanel.Variant(gene = "ATP7B", clazz = Clazz.BV, hgvsc = "c.1366G>C", hgvsp = "p.Val456Leu", disease = "WD", zygosity = "Hom", inheritance = "AR", snv = "hg19:13:052544805:C:G", analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022", diseaseFullName = null, interpretation = null, genPhenDb = null)
            ); appendVariant(InterpretationPanel.Variant(gene = "ATP7B", clazz = Clazz.BV, hgvsc = "c.2495A>G", hgvsp = "p.Lys832Arg", disease = "WD", zygosity = "Hom", inheritance = "AR", snv = "hg19:13:052524488:T:C", analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022", diseaseFullName = null, interpretation = null, genPhenDb = null)); appendVariant(
                InterpretationPanel.Variant(gene = "ATP7B", clazz = Clazz.BV, hgvsc = "c.2855G>A", hgvsp = "p.Arg952Lys", disease = "WD", zygosity = "Hom", inheritance = "AR", snv = "hg19:13:052544805:C:G", analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022", diseaseFullName = null, interpretation = null, genPhenDb = null)
            ); appendVariant(InterpretationPanel.Variant(gene = "ATP7B", clazz = Clazz.BV, hgvsc = "c.3419T>C", hgvsp = "p.Val1140Ala", disease = "WD", zygosity = "Hom", inheritance = "AR", snv = "hg19:13:052515354:A:G", analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022", diseaseFullName = null, interpretation = null, genPhenDb = null)); appendVariant(
                InterpretationPanel.Variant(gene = "ATP7B", clazz = Clazz.BV, hgvsc = "c.3903+6C>T", hgvsp = "p.?", disease = "WD", zygosity = "Hom", inheritance = "AR", snv = "hg19:13:052511606:G:A", analysis = "01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022", diseaseFullName = null, interpretation = null, genPhenDb = null)
            )
            }.build()
            , mapOf(
                "ATP7B" to listOf(Disease("Wilson disease", "WD", listOf("AR")))
            ), null)
        val result = interpreter.interpret(202105251715184, "S065", param).block()
        println(om.writeValueAsString(result))
        kotlin.test.assertEquals(
            om.readValue("{\"result\":\"NEGATIVE\",\"result_text\":\"질환과 관련된 변이는 발견되지 않았습니다.\",\"reason_for_referral\":\"R/O Wilson disease\",\"clinical_information\":null,\"abbreviation_reference\":\"NM_000053.4(ATP7B)\",\"abbreviation_disease\":\"WD, Wilson disease\",\"abbreviation\":\"Hom, Homozygous; AR, Autosomal recessive; BV, Benign Variant\",\"interpretation\":\"ATP7B 유전자에서 Benign Variant (BV)가 발견되었습니다.\\n\\nATP7B 유전자의 c.1216T>G (p.Ser406Ala) 변이는 전체 인구 집단(gnomAD)에서의 minor allele frequency (MAF)가 44.1684%이며 한국인 인구 집단(KRGDB)에서는 51.4091%인 변이로, in-silico prediction(SIFT, PolyPhen, MutationTaster)에서는 Tolerated로 예측되었습니다. 이 변이는 기존에 Reduced copper accumulation 환자에서 보고된 바 있으며(PMID: 22240481), ClinVar에서 BV로 분류되어 있습니다(ID: 35701).\\n\\nATP7B 유전자는 WD 관련 유전자로 AR 유전 양상을 보입니다.\\n\\nATP7B 유전자의 c.1366G>C (p.Val456Leu) 변이는 전체 인구 집단(gnomAD)에서의 MAF가 43.7699%이며 한국인 인구 집단(KRGDB)에서는 47.1364%인 변이로, in-silico prediction(SIFT, PolyPhen, MutationTaster)에서는 Tolerated로 예측되었습니다. 이 변이는 기존에  association with 환자에서 보고된 바 있으며(PMID: 23830383), ClinVar에서 BV로 분류되어 있습니다(ID: 35702).\\n\\nATP7B 유전자는 WD 관련 유전자로 AR 유전 양상을 보입니다.\\n\\nATP7B 유전자의 c.2495A>G (p.Lys832Arg) 변이는 전체 인구 집단(gnomAD)에서의 MAF가 53.9808%이며 한국인 인구 집단(KRGDB)에서는 39.0000%인 변이로, in-silico prediction(SIFT, PolyPhen, MutationTaster)에서는 Tolerated로 예측되었습니다. 이 변이는 기존에  association with 환자에서 보고된 바 있으며(PMID: 21760992), ClinVar에서 BV로 분류되어 있습니다(ID: 35707).\\n\\nATP7B 유전자는 WD 관련 유전자로 AR 유전 양상을 보입니다.\\n\\nATP7B 유전자의 c.2855G>A (p.Arg952Lys) 변이는 전체 인구 집단(gnomAD)에서의 MAF가 43.7699%이며 한국인 인구 집단(KRGDB)에서는 47.1364%인 변이로, in-silico prediction(SIFT, PolyPhen, MutationTaster)에서는 Tolerated로 예측되었습니다. 이 변이는 기존에  association with 환자에서 보고된 바 있으며(PMID: 23830383), ClinVar에서 BV로 분류되어 있습니다(ID: 35702).\\n\\nATP7B 유전자는 WD 관련 유전자로 AR 유전 양상을 보입니다.\\n\\nATP7B 유전자의 c.3419T>C (p.Val1140Ala) 변이는 전체 인구 집단(gnomAD)에서의 MAF가 56.9698%이며 한국인 인구 집단(KRGDB)에서는 39.1818%인 변이로, in-silico prediction(SIFT, PolyPhen, MutationTaster)에서는 Tolerated로 예측되었습니다. 이 변이는 기존에 WD 환자에서 보고된 바 있으며(PMID: 14966923), ClinVar에서 BV로 분류되어 있습니다(ID: 35720).\\n\\nATP7B 유전자는 WD 관련 유전자로 AR 유전 양상을 보입니다.\\n\\nATP7B 유전자의 c.3903+6C>T (p.?) 변이는 전체 인구 집단(gnomAD)에서의 MAF가 53.8658%이며 한국인 인구 집단(KRGDB)에서는 38.7273%인 변이입니다. 이 변이는 기존에 WD 환자에서 보고된 바 있으며(PMID: 17264425), ClinVar에서 BV/LBV로 분류되어 있습니다(ID: 35727).\\n\\nATP7B 유전자는 WD 관련 유전자로 AR 유전 양상을 보입니다.\",\"mean_depth\":null,\"coverage\":null,\"variants\":[{\"snv\":\"hg19:13:052548140:A:C\",\"analysis\":\"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\",\"gene\":\"ATP7B\",\"hgvsc\":\"c.1216T>G\",\"hgvsp\":\"p.Ser406Ala\",\"zygosity\":\"Hom\",\"disease\":\"WD\",\"disease_full_name\":\"Wilson disease\",\"inheritance\":\"AR\",\"class\":\"BV\"},{\"snv\":\"hg19:13:052544805:C:G\",\"analysis\":\"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\",\"gene\":\"ATP7B\",\"hgvsc\":\"c.1366G>C\",\"hgvsp\":\"p.Val456Leu\",\"zygosity\":\"Hom\",\"disease\":\"WD\",\"disease_full_name\":\"Wilson disease\",\"inheritance\":\"AR\",\"class\":\"BV\"},{\"snv\":\"hg19:13:052524488:T:C\",\"analysis\":\"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\",\"gene\":\"ATP7B\",\"hgvsc\":\"c.2495A>G\",\"hgvsp\":\"p.Lys832Arg\",\"zygosity\":\"Hom\",\"disease\":\"WD\",\"disease_full_name\":\"Wilson disease\",\"inheritance\":\"AR\",\"class\":\"BV\"},{\"snv\":\"hg19:13:052544805:C:G\",\"analysis\":\"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\",\"gene\":\"ATP7B\",\"hgvsc\":\"c.2855G>A\",\"hgvsp\":\"p.Arg952Lys\",\"zygosity\":\"Hom\",\"disease\":\"WD\",\"disease_full_name\":\"Wilson disease\",\"inheritance\":\"AR\",\"class\":\"BV\"},{\"snv\":\"hg19:13:052515354:A:G\",\"analysis\":\"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\",\"gene\":\"ATP7B\",\"hgvsc\":\"c.3419T>C\",\"hgvsp\":\"p.Val1140Ala\",\"zygosity\":\"Hom\",\"disease\":\"WD\",\"disease_full_name\":\"Wilson disease\",\"inheritance\":\"AR\",\"class\":\"BV\"},{\"snv\":\"hg19:13:052511606:G:A\",\"analysis\":\"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\",\"gene\":\"ATP7B\",\"hgvsc\":\"c.3903+6C>T\",\"hgvsp\":\"p.?\",\"zygosity\":\"Hom\",\"disease\":\"WD\",\"disease_full_name\":\"Wilson disease\",\"inheritance\":\"AR\",\"class\":\"BV\"}],\"recommendation\":null,\"addendum\":null,\"incidental_findings\":null,\"authors\":[],\"revision\":false}", InterpretationPanel::class.java),
            result
        )
    }

    @Test
    @DisplayName("Panel Positive S061")
    fun testPositiveS061(){
        val param = ParameterPanel(
            ParameterPanel.Sex.M,
            InterpretationPanel.builder().apply {
                appendVariant(InterpretationPanel.Variant(gene = "MEN1", clazz = Clazz.LPV, hgvsc = "c.196_200dup", hgvsp = "p.Asp70Profs*51", disease = "MEN1", zygosity = "Het", inheritance = "AD", snv = "hg19:11:064577381:G:GGGGCT", analysis = "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003", diseaseFullName = null, interpretation = null, genPhenDb = null)); appendVariant(
                InterpretationPanel.Variant(gene = "MEN1", clazz = Clazz.BV, hgvsc = "c.1254C>T", hgvsp = "p.Asp418=", disease = "MEN1", zygosity = "Hom", inheritance = "AD", snv = "hg19:11:064572602:G:A", analysis = "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003", diseaseFullName = null, interpretation = null, genPhenDb = null)
            ); appendVariant(InterpretationPanel.Variant(gene = "MEN1", clazz = Clazz.BV, hgvsc = "c.1299T>C", hgvsp = "p.His433=", disease = "MEN1", zygosity = "Hom", inheritance = "AD", snv = "hg19:11:064572557:A:G", analysis = "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003", diseaseFullName = null, interpretation = null, genPhenDb = null)); appendVariant(
                InterpretationPanel.Variant(gene = "MEN1", clazz = Clazz.BV, hgvsc = "c.1621A>G", hgvsp = "p.Ala541=", disease = "MEN1", zygosity = "Hom", inheritance = "AD", snv = "hg19:11:064572018:T:C", analysis = "025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003", diseaseFullName = null, interpretation = null, genPhenDb = null)
            )
            }.build()
            , mapOf(
                "MEN1" to listOf(Disease("Multiple endocrine neoplasia 1", "MEN1", listOf("AD")))
            ), null)
        val result = interpreter.interpret(202106221715329, "S061", param).block()
        println(om.writeValueAsString(result))
        kotlin.test.assertEquals(
            om.readValue("{\"result\":\"POSITIVE\",\"result_text\":\"LPV가 발견되었습니다.\",\"reason_for_referral\":null,\"clinical_information\":null,\"abbreviation_reference\":\"NM_130799.2(MEN1)\",\"abbreviation_disease\":\"MEN1, Multiple endocrine neoplasia 1\",\"abbreviation\":\"Het, Heterozygous; Hom, Homozygous; AD, Autosomal dominant; LPV, Likely Pathogenic Variant; BV, Benign Variant\",\"interpretation\":\"MEN1 유전자에서 Likely Pathogenic Variant (LPV)와 Benign Variant (BV)가 발견되었습니다.\\n\\nMEN1 유전자의 c.196_200dup (p.Asp70Profs*51) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이입니다. 이 변이는 기존에 MEN1 환자에서 보고된 바 있습니다(PMID: 9683585).\\n\\nMEN1 유전자는 MEN1 관련 유전자로 AD 유전 양상을 보입니다.\\n\\nMEN1 유전자의 c.1254C>T (p.Asp418=) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이입니다. 이 변이는 ClinVar에서 BV로 분류되어 있습니다(ID: 96249).\\n\\nMEN1 유전자는 MEN1 관련 유전자로 AD 유전 양상을 보입니다.\\n\\nMEN1 유전자의 c.1299T>C (p.His433=) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이입니다. 이 변이는 ClinVar에서 BV로 분류되어 있습니다(ID: 167288).\\n\\nMEN1 유전자는 MEN1 관련 유전자로 AD 유전 양상을 보입니다.\\n\\nMEN1 유전자의 c.1621A>G (p.Ala541=) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이로, in-silico prediction(SIFT, MutationTaster)에서는 Tolerated로 예측되었습니다. 이 변이는 기존에 보고된 바 있으며(PMID: 18775714), ClinVar에서 BV로 분류되어 있습니다(ID: 134640).\\n\\nMEN1 유전자는 MEN1 관련 유전자로 AD 유전 양상을 보입니다.\",\"mean_depth\":null,\"coverage\":null,\"variants\":[{\"snv\":\"hg19:11:064577381:G:GGGGCT\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\",\"gene\":\"MEN1\",\"hgvsc\":\"c.196_200dup\",\"hgvsp\":\"p.Asp70Profs*51\",\"zygosity\":\"Het\",\"disease\":\"MEN1\",\"disease_full_name\":\"Multiple endocrine neoplasia 1\",\"inheritance\":\"AD\",\"class\":\"LPV\"},{\"snv\":\"hg19:11:064572602:G:A\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\",\"gene\":\"MEN1\",\"hgvsc\":\"c.1254C>T\",\"hgvsp\":\"p.Asp418=\",\"zygosity\":\"Hom\",\"disease\":\"MEN1\",\"disease_full_name\":\"Multiple endocrine neoplasia 1\",\"inheritance\":\"AD\",\"class\":\"BV\"},{\"snv\":\"hg19:11:064572557:A:G\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\",\"gene\":\"MEN1\",\"hgvsc\":\"c.1299T>C\",\"hgvsp\":\"p.His433=\",\"zygosity\":\"Hom\",\"disease\":\"MEN1\",\"disease_full_name\":\"Multiple endocrine neoplasia 1\",\"inheritance\":\"AD\",\"class\":\"BV\"},{\"snv\":\"hg19:11:064572018:T:C\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\",\"gene\":\"MEN1\",\"hgvsc\":\"c.1621A>G\",\"hgvsp\":\"p.Ala541=\",\"zygosity\":\"Hom\",\"disease\":\"MEN1\",\"disease_full_name\":\"Multiple endocrine neoplasia 1\",\"inheritance\":\"AD\",\"class\":\"BV\"}],\"recommendation\":null,\"addendum\":null,\"incidental_findings\":null,\"authors\":[],\"revision\":false}", InterpretationPanel::class.java),
            result
        )
    }

    @Test
    @DisplayName("Panel Negative S030 Addendum")
    fun testNegativeS030withAddendum(){
        val param = om.readValue(
            "{\"sex\" : \"F\", \"disease\": {\"F10\": [{\"full_name\": \"Factor X deficiency\", \"abbreviation\": \"FXD\", \"inheritance\": [\"AR\"]}]}, \"suffix\": \"Clinical correlation 및 가족검사가 권장됩니다.\", \"previous\": {\"result\": \"NEGATIVE\", \"result_text\": \"질환과 관련된 변이는 발견되지 않았습니다. [ADDENDUM RESULT 참조]\", \"variants\": [], \"abbreviation_reference\": \"\", \"abbreviation_disease\": \"\", \"abbreviation\": \"\", \"interpretation\": \"F8 유전자의 모든 exon과 인접 intron의 염기서열을 분석한 결과, 질환 관련 변이는 발견되지 않았습니다.\", \"reason_for_referral\": \"R/O Hemophilia (혈액형: A+, FX: 40%)\", \"addendum\": {\"result_text\": \"추가로 분석된 F10 유전자에서 VUS가 발견되었습니다.\", \"variants\": [{\"snv\": \"hg19:13:113803609:C:G\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:22AN003:007\", \"gene\": \"F10\", \"hgvsc\": \"c.1245C>G\", \"hgvsp\": \"p.Cys415Trp\", \"zygosity\": \"Het\", \"disease\": \"F10D\", \"inheritance\": \"AR\", \"class\": \"VUS\"}], \"abbreviation_reference\": \"NM_000504.4(F10)\", \"abbreviation_disease\": \"F10D, Factor X deficiency\", \"abbreviation\": \"AR, Autosomal recessive; Het, Heterozygous; VUS, Variant of Uncertain Significance\", \"interpretation\": \"F10 유전자의 c.1245C>G (p.Cys415Trp) 변이는 일반 인구집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이로,  in-silico prediction (SIFT, PolyPhen, MutationTaster)에서는 Deleterious로 예측되었습니다. 이 변이는 질환 관련성에 대한 근거가 불충분하여 VUS로 분류됩니다.\\n\\nF10 유전자는 F10D 관련 유전자로 AR 유전 양상을 보입니다.\\n\\n상염색체 열성 질환에서 한 개의 Heterozygous VUS 변이만이 발견된 경우, 1) 이 변이가 질환과 관련이 없는 변이일 가능성, 2) 실제 질환과 관련이 있지만 보인자일 가능성, 3) 실제 이 유전자와 관련된 질환을 가지고 있지만 나머지 하나의 대립 유전자가 본 검사로 검출되지 않는 종류의 변이(large deletion or insertion, deep intronic variant, etc.)를 동반할 가능성 등이 있습니다. 상염색체 열성 유전 질환에서 한 개의 VUS가 발견된 경우, 가족검사를 시행하더라도 변이의 Pathogenicity를 판단하는데 도움이 되지 않으므로 가족검사가 권장되지 않습니다. Clinical correlation이 권장되며, 임상적으로 필요하다고 판단될 경우 deep intronic variant, large deletion/insertion 등을 검출하기 위한 추가 검사(Diagnostic Genome Sequencing 등)를 고려하시기 바랍니다.\"}}}",
            ParameterPanel::class.java
        )
        val result = interpreter.interpret(202208011715110, "S030", param).block()
        println(om.writeValueAsString(result))
        kotlin.test.assertEquals(
            om.readValue(
                "{\"result\":\"NEGATIVE\",\"result_text\":\"질환과 관련된 변이는 발견되지 않았습니다. [ADDENDUM RESULT 참조]\",\"reason_for_referral\":\"R/O Hemophilia A\",\"clinical_information\":null,\"abbreviation_reference\":\"\",\"abbreviation_disease\":\"\",\"abbreviation\":\"\",\"interpretation\":\"F8 유전자의 모든 exon과 인접 intron의 염기서열을 분석한 결과, 질환 관련 변이는 발견되지 않았습니다.\\n\\n- Mature protein:\\n- Reported severity:\\n- History of inhibitor:\\n- Reference ID:\\n- Year reported:\\n\\nClinical correlation 및 가족검사가 권장됩니다.\",\"mean_depth\":null,\"coverage\":null,\"variants\":[],\"recommendation\":null,\"addendum\":{\"result\":\"INCONCLUSIVE\",\"result_text\":\"추가로 분석된 F10 유전자에서 VUS가 발견되었습니다.\",\"reason_for_referral\":null,\"clinical_information\":null,\"abbreviation_reference\":\"NM_000504.4(F10)\",\"abbreviation_disease\":\"FXD, Factor X deficiency\",\"abbreviation\":\"Het, Heterozygous; AR, Autosomal recessive; VUS, Variant of Uncertain Significance\",\"interpretation\":\"F10 유전자의 c.1245C>G (p.Cys415Trp) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이로, in-silico prediction(SIFT, PolyPhen, MutationTaster)에서는 Deleterious로 예측되었습니다. 이 변이는 질환 관련성에 대한 근거가 불충분하여 VUS로 분류됩니다.\\n\\nF10 유전자는 FXD 관련 유전자로 AR 유전 양상을 보입니다.\",\"mean_depth\":null,\"coverage\":null,\"variants\":[{\"snv\":\"hg19:13:113803609:C:G\",\"analysis\":\"01db4ff4-9689-47b0-b0d9-1659788912c5:22AN003:007\",\"gene\":\"F10\",\"hgvsc\":\"c.1245C>G\",\"hgvsp\":\"p.Cys415Trp\",\"zygosity\":\"Het\",\"disease\":\"FXD\",\"disease_full_name\":\"Factor X deficiency\",\"inheritance\":\"AR\",\"class\":\"VUS\"}],\"recommendation\":null,\"addendum\":null,\"incidental_findings\":null,\"authors\":[],\"revision\":false},\"incidental_findings\":null,\"authors\":[],\"revision\":false}",
                InterpretationPanel::class.java
            ),
            result
        )
    }

    @Test
    @DisplayName("Panel Positive S061 Addendum")
    fun testPositiveS061withAddendum(){
        val param = om.readValue(
            "{\"sex\":\"M\",\"disease\":{\"MEN1\":[{\"full_name\":\"Multiple endocrine neoplasia 1\",\"abbreviation\":\"MEN1\",\"inheritance\":[\"AD\"]}],\"ATM\":[{\"full_name\":\"{Breast cancer, susceptibility to}\",\"abbreviation\":\"CST\",\"inheritance\":[\"AD\",\" somatic mutation\"]}]},\"previous\":{\"result\":\"POSITIVE\",\"result_text\":\"LPV가 발견되었습니다. [ADDENDUM RESULT 참조]\",\"variants\":[{\"snv\":\"hg19:11:064574565:G:T\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004\",\"gene\":\"MEN1\",\"hgvsc\":\"c.830C>A\",\"hgvsp\":\"p.Pro277His\",\"zygosity\":\"Het\",\"disease\":\"MEN1\",\"inheritance\":\"AD\",\"class\":\"LPV\"}],\"abbreviation_reference\":\"NM_130799.2(MEN1)\",\"abbreviation_disease\":\"MEN1, Multiple endocrine neoplasia 1\",\"abbreviation\":\"AD, Autosomal dominant; Het, Heterozygous; LPV, Likely Pathogenic Variant\",\"interpretation\":\"MEN1 유전자의 c.830C>A (p.Pro277His) 변이는 일반 인구집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이입니다.  해당 변이는 Functional study를 통해 단백 기능 저하를 일으키는 것으로 보고되어 있으며 (PMID 21819486),  ClinVar에서는 LPV(1) 혹은 VUS(1)로 분류되어 있습니다 (ID: 403801).\\n\\nMEN1 유전자는 MEN1 관련 유전자로 AD 유전 양상을 보입니다.\",\"addendum\":{\"result_text\":\"추가로 분석된 ATM 유전자에서 Pathogenic Variant (PV)가 발견되었습니다.\",\"variants\":[{\"snv\":\"hg19:11:108213957:CCT:C\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004\",\"gene\":\"ATM\",\"hgvsc\":\"c.8283_8284del\",\"hgvsp\":\"p.Gln2762AlafsTer6\",\"zygosity\":\"Het\",\"disease\":\"sBC\",\"inheritance\":\"AD\",\"class\":\"PV\"}],\"abbreviation_reference\":\"NM_000051.3(ATM)\",\"abbreviation_disease\":\"Breast cancer, susceptibility to\",\"abbreviation\":\"AD, Autosomal dominant; Het, Heterozygous; PV, Pathogenic Variant\",\"interpretation\":\"ATM 유전자의 c.8283_8284del (p.Gln2762AlafsTer6) 변이는 8283번째부터 8284번째 염기가 삭제되어 해석틀 이동을 일으키고, 이로인해 조기에 종결코돈을 형성할 것으로 예상되는 변이로, 일반 인구집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이입니다.  이 변이는 ClinVar에서 PV로 분류되어 있습니다(ID: 482713).\\n\"}}}",
            ParameterPanel::class.java
        )
        val value = interpreter.interpret(202109011715037, "S061", param).block()
        println(om.writeValueAsString(value))
        kotlin.test.assertEquals(
            om.readValue(
                "{\"result\":\"POSITIVE\",\"result_text\":\"LPV가 발견되었습니다. [ADDENDUM RESULT 참조]\",\"reason_for_referral\":null,\"clinical_information\":null,\"abbreviation_reference\":\"NM_130799.2(MEN1)\",\"abbreviation_disease\":\"MEN1, Multiple endocrine neoplasia 1\",\"abbreviation\":\"Het, Heterozygous; AD, Autosomal dominant; LPV, Likely Pathogenic Variant\",\"interpretation\":\"MEN1 유전자에서 Likely Pathogenic Variant (LPV)가 발견되었습니다.\\n\\nMEN1 유전자의 c.830C>A (p.Pro277His) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이로, in-silico prediction(SIFT, MutationTaster)에서는 Deleterious로 예측되었습니다. 이 변이는 기존에 보고된 바 있으며(PMID: 12016470), ClinVar에서 LPV(1),VUS(1)로 분류되어 있습니다(ID: 403801).\\n\\nMEN1 유전자는 MEN1 관련 유전자로 AD 유전 양상을 보입니다.\",\"mean_depth\":null,\"coverage\":null,\"variants\":[{\"snv\":\"hg19:11:064574565:G:T\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004\",\"gene\":\"MEN1\",\"hgvsc\":\"c.830C>A\",\"hgvsp\":\"p.Pro277His\",\"zygosity\":\"Het\",\"disease\":\"MEN1\",\"disease_full_name\":\"Multiple endocrine neoplasia 1\",\"inheritance\":\"AD\",\"class\":\"LPV\"}],\"recommendation\":null,\"addendum\":{\"result\":\"NEGATIVE\",\"result_text\":\"추가로 분석된 ATM 유전자에서 PV가 발견되었습니다.\",\"reason_for_referral\":null,\"clinical_information\":null,\"abbreviation_reference\":\"NM_000051.3(ATM)\",\"abbreviation_disease\":\"CST, {Breast cancer, susceptibility to}\",\"abbreviation\":\"Het, Heterozygous; AD, Autosomal dominant; PV, Pathogenic Variant\",\"interpretation\":\"ATM 유전자의 c.8283_8284del (p.Gln2762AlafsTer6) 변이는 일반 인구 집단(gnomAD, KRGDB)에서 보고된 바 없는 매우 드문 변이입니다. 이 변이는 기존에 보고된 바 있으며(PMID: 8845835), ClinVar에서 PV로 분류되어 있습니다(ID: 482713).\\n\\nATM 유전자는 CST 관련 유전자로 AD 또는 somatic mutation 유전 양상을 보입니다.\",\"mean_depth\":null,\"coverage\":null,\"variants\":[{\"snv\":\"hg19:11:108213957:CCT:C\",\"analysis\":\"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004\",\"gene\":\"ATM\",\"hgvsc\":\"c.8283_8284del\",\"hgvsp\":\"p.Gln2762AlafsTer6\",\"zygosity\":\"Het\",\"disease\":\"CST\",\"disease_full_name\":\"{Breast cancer, susceptibility to}\",\"inheritance\":\"AD,  somatic mutation\",\"class\":\"PV\"}],\"recommendation\":null,\"addendum\":null,\"incidental_findings\":null,\"authors\":[],\"revision\":false},\"incidental_findings\":null,\"authors\":[],\"revision\":false}",
                InterpretationPanel::class.java
            ),
            value
        )
    }


    val PV1 = "{\"hgmd.mut\": \"ALT\", \"insilico_sanger\": \"Y\", \"ge_green\": \"Severe Paediatric Disorders | Gene therapy clinical trials | Bleeding and platelet disorders | Inherited bleeding disorders\", \"hgmd.hgvsp\": \"[\\\"p.?\\\"]\", \"hgmd.web.literature\": \"{2. Xiong (2015) Science 347: 1254806 PubMed: 25525159 RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. | Additional literature report | dm:additional reference supporting inclusion | predicted to induce a large splicing change - Table S4.}\", \"effect_level\": \"HIGH\", \"hgvsc\": \"[\\\"NM_001313913.1:c.278-2A>T\\\",\\\"NM_000133.4:c.392-2A>T\\\"]\", \"ada_score\": \"0.999967305459904\", \"reference\": \"hg19\", \"ref\": \"A\", \"strand\": \"true\", \"pos\": \"138630520\", \"hgmd.hgvsc\": \"[\\\"NM_000133.4:c.392-2A>T\\\"]\", \"vaf\": \"0.488721804511\", \"class_order\": \"10\", \"class\": \"PVS1\", \"hgvsp\": \"[\\\"p.?\\\"]\", \"splicing_distance\": \"2\", \"organism\": \"homo sapiens\", \"rf_score\": \"0.946\", \"mim.disease\": \"Thrombophilia, X-linked, due to factor IX defect, 300807 (3), X-linked recessive | {Deep venous thrombosis, protection against}, 300807 (3), X-linked recessive | Hemophilia B, 306900 (3), X-linked recessive | {Warfarin sensitivity}, 301052 (3), X-linked\", \"ge_class\": \"Green\", \"so_term\": \"[\\\"splice_acceptor_variant\\\"]\", \"hgmd.web.tag\": \"DM\", \"alt\": \"T\", \"gene.refgene\": \"F9\", \"spliceai_ds_max\": \"0.55\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:22GMD029:029\", \"sample\": \"22GMD029_20220323-171-5095_F9-29_M\", \"disease_description\": \"DISEASE: Hemophilia B (HEMB) [MIM:306900]: An X-linked blood coagulation disorder characterized by a permanent tendency to hemorrhage, due to factor IX deficiency. It is phenotypically similar to hemophilia A, but patients present with fewer symptoms. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. {ECO:0000269|PubMed:10094553, ECO:0000269|PubMed:10698280, ECO:0000269|PubMed:11122099, ECO:0000269|PubMed:12588353, ECO:0000269|PubMed:12604421, ECO:0000269|PubMed:1346975, ECO:0000269|PubMed:1615485, ECO:0000269|PubMed:1902289, ECO:0000269|PubMed:1958666, ECO:0000269|PubMed:2162822, ECO:0000269|PubMed:2339358, ECO:0000269|PubMed:2372509, ECO:0000269|PubMed:2472424, ECO:0000269|PubMed:25251685, ECO:0000269|PubMed:25470321, ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:2713493, ECO:0000269|PubMed:2714791, ECO:0000269|PubMed:2738071, ECO:0000269|PubMed:2753873, ECO:0000269|PubMed:2773937, ECO:0000269|PubMed:2775660, ECO:0000269|PubMed:3009023, ECO:0000269|PubMed:3243764, ECO:0000269|PubMed:3401602, ECO:0000269|PubMed:3790720, ECO:0000269|PubMed:6603618, ECO:0000269|PubMed:7981722, ECO:0000269|PubMed:8076946, ECO:0000269|PubMed:8199596, ECO:0000269|PubMed:8257988, ECO:0000269|PubMed:8295821, ECO:0000269|PubMed:8680410, ECO:0000269|PubMed:9169594, ECO:0000269|PubMed:9222764, ECO:0000269|PubMed:9452115, ECO:0000269|PubMed:9590153, ECO:0000269|PubMed:9600455}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Mutations in position 43 (Oxford-3, San Dimas) and 46 (Cambridge) prevents cleavage of the propeptide (PubMed:12588353, PubMed:2738071, PubMed:3009023, PubMed:8295821, PubMed:9169594, PubMed:9600455, PubMed:25251685). Mutation in position 93 (Alabama) probably fails to bind to cell membranes (PubMed:3790720). Mutation in position 191 (Chapel-Hill) or in position 226 (Nagoya or Hilo) prevent cleavage of the activation peptide (PubMed:6603618, PubMed:8076946, PubMed:12588353, PubMed:2162822, PubMed:25251685, PubMed:2713493). {ECO:0000269|PubMed:12588353, ECO:0000269|PubMed:2162822, ECO:0000269|PubMed:25251685, ECO:0000269|PubMed:2713493, ECO:0000269|PubMed:2738071, ECO:0000269|PubMed:3009023, ECO:0000269|PubMed:3790720, ECO:0000269|PubMed:6603618, ECO:0000269|PubMed:8076946, ECO:0000269|PubMed:8295821, ECO:0000269|PubMed:9169594, ECO:0000269|PubMed:9600455}.; DISEASE: Thrombophilia, X-linked, due to factor IX defect (THPH8) [MIM:300807]: A hemostatic disorder characterized by a tendency to thrombosis. {ECO:0000269|PubMed:19846852}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"hgmd.codon.disease\": \"Hemophilia_B\", \"gnomad.total\": \"0\", \"tags\": \"[\\\"candidate\\\",\\\"all\\\"]\", \"genotype\": \"0/1\", \"chrom\": \"chrX\", \"filter\": \"PASS\", \"mim.inheritance\": \"[\\\"XR\\\",\\\"XL\\\"]\", \"depth\": \"266\", \"hgmd.tag\": \"DM\", \"qual\": \"3495.64\", \"snv\": \"hg19:X:138630520:A:T\", \"create_at\": \"2022-04-04T05:49:54.537\", \"hgmd.pmid\": \"10090477\", \"function_description\": \"FUNCTION: Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. {ECO:0000269|PubMed:1730085, ECO:0000269|PubMed:19846852, ECO:0000269|PubMed:20121197, ECO:0000269|PubMed:20121198, ECO:0000269|PubMed:2592373, ECO:0000269|PubMed:8295821}.; \"}"
    val LPV1 = "{\"hgmd.mut\": \"ALT\", \"gerp++.rs\": \"4.04\", \"polyphen2.hvar.score\": \"0.988\", \"intervar_\": \"Likely pathogenic\", \"fathmm-mkl_coding.pred\": \"D\", \"siphy_29way_logodds\": \"9.023\", \"hgvsc\": \"[\\\"NM_001276761.2:c.740A>C\\\",\\\"NM_000546.5:c.857A>C\\\",\\\"NM_001126112.2:c.857A>C\\\",\\\"NM_001126113.2:c.857A>C\\\",\\\"NM_001126114.2:c.857A>C\\\",\\\"NM_001126115.1:c.461A>C\\\",\\\"NM_001126116.1:c.461A>C\\\",\\\"NM_001126117.1:c.461A>C\\\",\\\"NM_001126118.1:c.740A>C\\\",\\\"NM_001276695.2:c.740A>C\\\",\\\"NM_001276696.2:c.740A>C\\\",\\\"NM_001276697.2:c.380A>C\\\",\\\"NM_001276698.2:c.380A>C\\\",\\\"NM_001276699.2:c.380A>C\\\",\\\"NM_001276760.2:c.740A>C\\\"]\", \"reference\": \"hg19\", \"go.molecular_function\": \"[\\\"RNA polymerase II regulatory region sequence-specific DNA binding\\\",\\\"RNA polymerase II transcription factor activity, sequence-specific DNA binding\\\",\\\"transcription factor activity, core RNA polymerase binding\\\",\\\"core promoter sequence-specific DNA binding\\\",\\\"RNA polymerase II transcription factor binding\\\",\\\"transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding\\\",\\\"protease binding\\\",\\\"p53 binding\\\",\\\"DNA binding\\\",\\\"chromatin binding\\\",\\\"damaged DNA binding\\\",\\\"transcription factor activity, sequence-specific DNA binding\\\",\\\"mRNA 3'-UTR binding\\\",\\\"copper ion binding\\\",\\\"protein binding\\\",\\\"ATP binding\\\",\\\"transcription factor binding\\\",\\\"zinc ion binding\\\",\\\"enzyme binding\\\",\\\"protein kinase binding\\\",\\\"protein phosphatase binding\\\",\\\"receptor tyrosine kinase binding\\\",\\\"ubiquitin protein ligase binding\\\",\\\"histone acetyltransferase binding\\\",\\\"identical protein binding\\\",\\\"histone deacetylase binding\\\",\\\"protein self-association\\\",\\\"transcription regulatory region DNA binding\\\",\\\"protein heterodimerization activity\\\",\\\"protein N-terminus binding\\\",\\\"chaperone binding\\\",\\\"protein phosphatase 2A binding\\\",\\\"disordered domain specific binding\\\"]\", \"vest3_score\": \"0.872\", \"ref\": \"T\", \"phastcons20way_mammalian\": \"0.995\", \"gerp++.gt2\": \"4.04\", \"cadd.raw\": \"5.065\", \"gene.full_name\": \"tumor protein p53\", \"brca2457_freq\": \"0\", \"vaf\": \"0.61744966443\", \"intervar.evidence_\": \"PM1:1 PM2:1 PP3:1 PP5:1\", \"mutationtaster.score\": \"1.000\", \"class_order\": \"25\", \"hgvsp\": \"[\\\"p.Glu247Ala\\\",\\\"p.Glu286Ala\\\",\\\"p.Glu286Ala\\\",\\\"p.Glu286Ala\\\",\\\"p.Glu286Ala\\\",\\\"p.Glu154Ala\\\",\\\"p.Glu154Ala\\\",\\\"p.Glu154Ala\\\",\\\"p.Glu247Ala\\\",\\\"p.Glu247Ala\\\",\\\"p.Glu247Ala\\\",\\\"p.Glu127Ala\\\",\\\"p.Glu127Ala\\\",\\\"p.Glu127Ala\\\",\\\"p.Glu247Ala\\\"]\", \"provean.score\": \"-5.49\", \"phylop20way_mammalian\": \"1.058\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"essential_gene\": \"E\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"alt\": \"G\", \"cadd.pred\": \"25.3\", \"sift.pred\": \"D\", \"gene.refgene\": \"TP53\", \"spliceai_ds_max\": \"0\", \"mutationassessor.pred\": \"M\", \"lrt.score\": \"0.000\", \"polyphen2.hdiv.score\": \"0.999\", \"analysis\": \"a118c948-74b9-4929-abf9-35d8a50e6f37:22BRCA027:008\", \"dann.score\": \"0.993\", \"p(hi)\": \"0.99999\", \"tags\": \"[\\\"candidate\\\",\\\"all\\\"]\", \"genotype\": \"0/1\", \"clinvar.updated_class\": \"Likely pathogenic\", \"metalr.score\": \"0.993\", \"hgmd.tag\": \"DM\", \"metasvm.pred\": \"D\", \"krg_db_1100\": \"0\", \"hgmd.pmid\": \"1569604\", \"insilico_sanger\": \"N\", \"hgmd.hgvsp\": \"[\\\"p.Glu286Ala\\\"]\", \"hgmd.web.literature\": \"{1. Sameshima (1992) J Natl Cancer Inst 84: 703 PubMed: 1569604 Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. | Primary literature report | dm:original reference supporting inclusion | No comments},{2. Monti (2007) Clin Cancer Res 13: 3789 PubMed: 17606709 Transcriptional functionality of germ line p53 mutants influences cancer phenotype. | Functional characterisation | dm:additional reference supporting inclusion | Severe deficiency allele. Descr. in Suppl. Table S1A (online).},{3. Malcikova (2010) Biol Chem 391: 197 PubMed: 20128691 Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. | Functional characterisation | . | None},{4. Monti (2011) Mol Cancer Res 9: 271 PubMed: 21343334 Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. | Functional characterisation | dm:additional reference supporting inclusion | Severe deficiency, dominant negative allele. Descr. in Suppl. Tables 1 and 3 (online).}\", \"mutationassessor.score\": \"3.28\", \"effect_level\": \"MED\", \"interpro_domain\": \"p53, DNA-binding domain|p53-like transcription factor, DNA-binding|p53/RUNT-type transcription factor, DNA-binding domain\", \"clinvar.clndbn\": \"[\\\"Hepatocellular_carcinoma\\\",\\\"Acute_myeloid_leukemia\\\",\\\"Pancreatic_adenocarcinoma\\\",\\\"Squamous_cell_carcinoma_of_the_skin\\\",\\\"Transitional_cell_carcinoma_of_the_bladder\\\",\\\"Breast_neoplasm\\\",\\\"Carcinoma_of_esophagus\\\",\\\"Malignant_melanoma_of_skin\\\",\\\"Lung_adenocarcinoma\\\",\\\"Small_cell_lung_carcinoma\\\",\\\"Neoplasm_of_brain\\\",\\\"Neoplasm_of_the_large_intestine\\\",\\\"Adenocarcinoma_of_stomach\\\",\\\"Ovarian_Serous_Cystadenocarcinoma\\\",\\\"Squamous_cell_carcinoma_of_the_head_and_neck\\\"]\", \"metasvm.score\": \"1.001\", \"polyphen2.hdiv.pred\": \"D\", \"mim.phenotype_id\": \"[\\\"133239\\\",\\\"151623\\\",\\\"202300\\\",\\\"211980\\\",\\\"260500\\\",\\\"275355\\\",\\\"614740\\\"]\", \"fathmm.pred\": \"D\", \"strand\": \"false\", \"sift.score\": \"0\", \"pos\": \"7577081\", \"lrt.pred\": \"D\", \"mgi_mouse.gene\": \"Trp53\", \"go.cellular_component\": \"[\\\"nuclear chromatin\\\",\\\"intracellular\\\",\\\"nucleus\\\",\\\"nucleoplasm\\\",\\\"replication fork\\\",\\\"transcription factor TFIID complex\\\",\\\"nucleolus\\\",\\\"cytoplasm\\\",\\\"mitochondrion\\\",\\\"mitochondrial matrix\\\",\\\"endoplasmic reticulum\\\",\\\"cytosol\\\",\\\"nuclear matrix\\\",\\\"nuclear body\\\",\\\"PML body\\\",\\\"protein complex\\\"]\", \"p(rec)\": \"0.99980\", \"m-cap.score\": \"0.719\", \"hgmd.hgvsc\": \"[\\\"NM_000546.5:c.857A>C\\\"]\", \"polyphen2.hvar.pred\": \"D\", \"fathmm-mkl_coding.score\": \"0.996\", \"class\": \"(L)PV\", \"fathmm.score\": \"-7.22\", \"provean.pred\": \"D\", \"go.biological_process\": \"[\\\"negative regulation of transcription from RNA polymerase II promoter\\\",\\\"DNA strand renaturation\\\",\\\"base-excision repair\\\",\\\"nucleotide-excision repair\\\",\\\"regulation of transcription, DNA-templated\\\",\\\"transcription from RNA polymerase II promoter\\\",\\\"protein complex assembly\\\",\\\"autophagy\\\",\\\"cellular response to DNA damage stimulus\\\",\\\"DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest\\\",\\\"DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator\\\",\\\"ER overload response\\\",\\\"cell cycle arrest\\\",\\\"Ras protein signal transduction\\\",\\\"multicellular organism development\\\",\\\"cell aging\\\",\\\"protein localization\\\",\\\"cell proliferation\\\",\\\"negative regulation of cell proliferation\\\",\\\"determination of adult lifespan\\\",\\\"response to X-ray\\\",\\\"response to gamma radiation\\\",\\\"positive regulation of gene expression\\\",\\\"viral process\\\",\\\"protein deubiquitination\\\",\\\"cell differentiation\\\",\\\"negative regulation of cell growth\\\",\\\"DNA damage response, signal transduction by p53 class mediator\\\",\\\"positive regulation of histone deacetylation\\\",\\\"chromatin assembly\\\",\\\"mitotic G1 DNA damage checkpoint\\\",\\\"positive regulation of protein oligomerization\\\",\\\"cellular response to UV\\\",\\\"cellular response to drug\\\",\\\"interleukin-7-mediated signaling pathway\\\",\\\"cellular response to glucose starvation\\\",\\\"intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator\\\",\\\"regulation of apoptotic process\\\",\\\"positive regulation of apoptotic process\\\",\\\"negative regulation of apoptotic process\\\",\\\"entrainment of circadian clock by photoperiod\\\",\\\"proteasome-mediated ubiquitin-dependent protein catabolic process\\\",\\\"positive regulation of neuron apoptotic process\\\",\\\"negative regulation of transcription, DNA-templated\\\",\\\"positive regulation of transcription, DNA-templated\\\",\\\"positive regulation of transcription from RNA polymerase II promoter\\\",\\\"response to antibiotic\\\",\\\"positive regulation of protein export from nucleus\\\",\\\"regulation of mitochondrial membrane permeability\\\",\\\"phosphatidylinositol-mediated signaling\\\",\\\"negative regulation of fibroblast proliferation\\\",\\\"circadian behavior\\\",\\\"positive regulation of peptidyl-tyrosine phosphorylation\\\",\\\"negative regulation of helicase activity\\\",\\\"protein tetramerization\\\",\\\"protein homotetramerization\\\",\\\"negative regulation of telomerase activity\\\",\\\"positive regulation of thymocyte apoptotic process\\\",\\\"positive regulation of cell cycle arrest\\\",\\\"cellular response to hypoxia\\\",\\\"cellular response to ionizing radiation\\\",\\\"cellular response to gamma radiation\\\",\\\"signal transduction by p53 class mediator\\\",\\\"intrinsic apoptotic signaling pathway by p53 class mediator\\\",\\\"cellular response to actinomycin D\\\",\\\"positive regulation of release of cytochrome c from mitochondria\\\",\\\"replicative senescence\\\",\\\"oxidative stress-induced premature senescence\\\",\\\"intrinsic apoptotic signaling pathway\\\",\\\"oligodendrocyte apoptotic process\\\",\\\"positive regulation of execution phase of apoptosis\\\",\\\"positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway\\\",\\\"regulation of signal transduction by p53 class mediator\\\",\\\"regulation of cell cycle G2/M phase transition\\\",\\\"positive regulation of pri-miRNA transcription from RNA polymerase II promoter\\\",\\\"positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress\\\",\\\"positive regulation of reactive oxygen species metabolic process\\\",\\\"positive regulation of intrinsic apoptotic signaling pathway\\\"]\", \"clinvar.class\": \"Likely_pathogenic\", \"m-cap.pred\": \"D\", \"clinvar.id\": \"376593\", \"mim.disease\": \"{Basal cell carcinoma 7}, 614740 (3), Autosomal dominant | {Adrenocortical carcinoma, pediatric}, 202300 (3), Autosomal dominant | Hepatocellular carcinoma, somatic, 114550 (3) | Breast cancer, somatic, 114480 (3) | Li-Fraumeni syndrome, 151623 (3), Autosomal dominant | Pancreatic cancer, somatic, 260350 (3) | Nasopharyngeal carcinoma, somatic, 607107 (3) | {Osteosarcoma}, 259500 (3), Somatic mutation | {Choroid plexus papilloma}, 260500 (3), Autosomal dominant | {Colorectal cancer}, 114500 (3), Somatic mutation, Autosomal dominant | {Glioma susceptibility 1}, 137800 (3), Somatic mutation, Autosomal dominant | Bone marrow failure syndrome 5, 618165 (3), Autosomal dominant\", \"hgmd.web.tag\": \"DM\", \"mgi_mouse.phenotype\": \"behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; embryo phenotype; neoplasm; pigmentation phenotype; normal phenotype; mortality/aging (characteristics involving the ability of an organism to live and age normally throughout development and life span); reproductive system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; limbs/digits/tail phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; renal/urinary system phenotype; skeleton phenotype; cellular phenotype; immune system phenotype; homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands); growth/size/body region phenotype; craniofacial phenotype; muscle phenotype;\", \"exon_in_hgmd\": \"[\\\"8/11\\\"]\", \"sample\": \"I_22BRCA027-08_22TP006_20220323-100-6001\", \"disease_description\": \"DISEASE: Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.; DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. {ECO:0000269|PubMed:10484981, ECO:0000269|PubMed:1565144, ECO:0000269|PubMed:1737852, ECO:0000269|PubMed:1933902, ECO:0000269|PubMed:1978757, ECO:0000269|PubMed:2259385, ECO:0000269|PubMed:7887414, ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign tumor of neuroectodermal origin that generally occurs in childhood, but has also been reported in adults. Although generally found within the ventricular system, choroid plexus papillomas can arise ectopically in the brain parenchyma or disseminate throughout the neuraxis. Patients present with signs and symptoms of increased intracranial pressure including headache, hydrocephalus, papilledema, nausea, vomiting, cranial nerve deficits, gait impairment, and seizures. {ECO:0000269|PubMed:12085209}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith- Wiedemann syndrome and Li-Fraumeni syndrome. {ECO:0000269|PubMed:11481490}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common malignant skin neoplasm that typically appears on hair-bearing skin, most commonly on sun-exposed areas. It is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter. {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;\", \"chrom\": \"chr17\", \"filter\": \"PASS\", \"codon\": \"gAa/gCa\", \"metalr.pred\": \"D\", \"mim.inheritance\": \"[\\\"AD\\\",\\\"Somatic mutation\\\",\\\"Somatic mutation, AD\\\"]\", \"depth\": \"149\", \"pathway(kegg)_full\": \"[\\\"MAPK signaling pathway\\\",\\\"Cell cycle\\\",\\\"p53 signaling pathway\\\",\\\"Apoptosis\\\",\\\"Wnt signaling pathway\\\",\\\"Amyotrophic lateral sclerosis (ALS)\\\",\\\"Huntington's disease\\\",\\\"Colorectal cancer\\\",\\\"Pancreatic cancer\\\",\\\"Endometrial cancer\\\",\\\"Glioma\\\",\\\"Prostate cancer\\\",\\\"Thyroid cancer\\\",\\\"Basal cell carcinoma\\\",\\\"Melanoma\\\",\\\"Bladder cancer\\\",\\\"Chronic myeloid leukemia\\\",\\\"Small cell lung cancer\\\",\\\"Non-small cell lung cancer\\\"]\", \"qual\": \"2370.77\", \"snv\": \"hg19:17:007577081:T:G\", \"create_at\": \"2022-03-30T20:19:14.709\", \"exon\": \"[\\\"8/11\\\",\\\"8/11\\\",\\\"8/11\\\",\\\"8/12\\\",\\\"8/12\\\",\\\"4/7\\\",\\\"4/8\\\",\\\"4/8\\\",\\\"7/10\\\",\\\"8/12\\\",\\\"8/12\\\",\\\"4/7\\\",\\\"4/8\\\",\\\"4/8\\\",\\\"8/11\\\"]\", \"trait_association(gwas)\": \"Basal cell carcinoma[21946351;24403052;25855136;27539887];Sex hormone levels[26014426];Esophageal squamous cell carcinoma[25129146];\", \"function_description\": \"FUNCTION: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA- Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1- mediated transcriptional activation of PER2 (PubMed:24051492). {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:9840937}.;\", \"mutationtaster.pred\": \"D\"}"
    val BV1 = "{\"hgmd.mut\": \"ALT\", \"ge_green\": \"White matter disorders - childhood onset | Structural basal ganglia disorders | Severe Paediatric Disorders | Neonatal cholestasis | Iron metabolism disorders | Childhood onset dystonia or chorea or related movement disorder | Adult onset movement disorder | Brain channelopathy | Early onset dystonia | Hereditary ataxia - adult onset | Hypotonic infant | Inborn errors of metabolism | Neurodegenerative disorders - adult onset | Paediatric disorders | Undiagnosed metabolic disorders\", \"af_1000g_eas\": \"0.5367\", \"hgvsc\": \"[\\\"NM_001330579.2:c.1216T>G\\\",\\\"NM_000053.4:c.1216T>G\\\",\\\"NM_001005918.3:c.1216T>G\\\",\\\"NM_001243182.1:c.883T>G\\\",\\\"NM_001330578.1:c.1216T>G\\\"]\", \"cadd.raw\": \"0.876507\", \"vaf\": \"0.965517241379\", \"hgvsp\": \"[\\\"p.Ser406Ala\\\",\\\"p.Ser406Ala\\\",\\\"p.Ser406Ala\\\",\\\"p.Ser295Ala\\\",\\\"p.Ser406Ala\\\"]\", \"gnomad.genome.eas\": \"5.25129e-01\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"gene.refgene\": \"ATP7B\", \"lrt.score\": \"0.665665\", \"exac.eas\": \"0.534\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\", \"tags\": \"[\\\"all\\\"]\", \"hgmd.tag\": \"FP\", \"intervar.evidence.pv\": \"PM1\", \"hgmd.pmid\": \"22240481\", \"polyphen.pred\": \"benign\", \"insilico_sanger\": \"Y\", \"polyphen.score\": \"0\", \"hgmd.hgvsp\": \"[\\\"p.Ser406Ala\\\"]\", \"effect_level\": \"MED\", \"clinvar.clndbn\": \"[\\\"Wilson_disease&not_specified\\\"]\", \"fathmm.pred\": \"D&D&D&D&D&.&D\", \"pos\": \"52548140\", \"lrt.pred\": \"N\", \"ge_amber\": \"Cholestasis | Rare genetic inflammatory skin disorders\", \"hgmd.hgvsc\": \"[\\\"NM_000053.4:c.1216T>G\\\"]\", \"clinvar.updated_review\": \"criteria provided, multiple submitters, no conflicts\", \"gnomad.exome.eas\": \"5.33319e-01\", \"exac.sas\": \"0.351\", \"fathmm.score\": \"-2.09&-2.09&-2.09&-2.09&-2.09&.&-2.09\", \"clinvar.id\": \"35701\", \"mim.disease\": \"Wilson disease, 277900 (3), Autosomal recessive\", \"hgmd.web.tag\": \"FP\", \"sample\": \"21GMD048_20210525-171-5184_ATP7B-22_M\", \"disease_description\": \"DISEASE: Wilson disease (WD) [MIM:277900]: An autosomal recessive disorder of copper metabolism in which copper cannot be incorporated into ceruloplasmin in liver, and cannot be excreted from the liver into the bile. Copper accumulates in the liver and subsequently in the brain and kidney. The disease is characterized by neurologic manifestations and signs of cirrhosis. {ECO:0000269|PubMed:10051024, ECO:0000269|PubMed:10194254, ECO:0000269|PubMed:10447265, ECO:0000269|PubMed:10453196, ECO:0000269|PubMed:10502776, ECO:0000269|PubMed:10502777, ECO:0000269|PubMed:10544227, ECO:0000269|PubMed:10721669, ECO:0000269|PubMed:10790207, ECO:0000269|PubMed:10942420, ECO:0000269|PubMed:11043508, ECO:0000269|PubMed:11093740, ECO:0000269|PubMed:11180609, ECO:0000269|PubMed:11216666, ECO:0000269|PubMed:11231950, ECO:0000269|PubMed:11243728, ECO:0000269|PubMed:11405812, ECO:0000269|PubMed:11690702, ECO:0000269|PubMed:11954751, ECO:0000269|PubMed:12325021, ECO:0000269|PubMed:12376745, ECO:0000269|PubMed:12544487, ECO:0000269|PubMed:14639035, ECO:0000269|PubMed:14966923, ECO:0000269|PubMed:14986826, ECO:0000269|PubMed:15024742, ECO:0000269|PubMed:15557537, ECO:0000269|PubMed:15811015, ECO:0000269|PubMed:15845031, ECO:0000269|PubMed:15952988, ECO:0000269|PubMed:15967699, ECO:0000269|PubMed:16088907, ECO:0000269|PubMed:16207219, ECO:0000269|PubMed:16283883, ECO:0000269|PubMed:16649058, ECO:0000269|PubMed:17718866, ECO:0000269|PubMed:17823867, ECO:0000269|PubMed:17919502, ECO:0000269|PubMed:17949296, ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:18373411, ECO:0000269|PubMed:19033537, ECO:0000269|PubMed:20333758, ECO:0000269|PubMed:21398519, ECO:0000269|PubMed:21454443, ECO:0000269|PubMed:21645214, ECO:0000269|PubMed:21682854, ECO:0000269|PubMed:22075048, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:22484412, ECO:0000269|PubMed:22763723, ECO:0000269|PubMed:23159873, ECO:0000269|PubMed:23235335, ECO:0000269|PubMed:23275100, ECO:0000269|PubMed:23333878, ECO:0000269|PubMed:23518715, ECO:0000269|PubMed:23962630, ECO:0000269|PubMed:24476933, ECO:0000269|PubMed:24555712, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:25704634, ECO:0000269|PubMed:25982861, ECO:0000269|PubMed:26004889, ECO:0000269|PubMed:28856630, ECO:0000269|PubMed:7626145, ECO:0000269|PubMed:8298641, ECO:0000269|PubMed:8533760, ECO:0000269|PubMed:8782057, ECO:0000269|PubMed:8931691, ECO:0000269|PubMed:8938442, ECO:0000269|PubMed:8980283, ECO:0000269|PubMed:9222767, ECO:0000269|PubMed:9311736, ECO:0000269|PubMed:9452121, ECO:0000269|PubMed:9482578, ECO:0000269|PubMed:9554743, ECO:0000269|PubMed:9671269, ECO:0000269|PubMed:9772425, ECO:0000269|PubMed:9829905, ECO:0000269|PubMed:9837819, ECO:0000269|PubMed:9887381}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"hgmd.codon.disease\": \"Reduced_copper_accumulation\", \"filter\": \"PASS\", \"depth\": \"87\", \"qual\": \"2710.06\", \"snv\": \"hg19:13:052548140:A:C\", \"function_description\": \"FUNCTION: Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}.; \", \"mutationtaster.pred\": \"P&P&P&P&P&P&P\", \"reference\": \"hg19\", \"ref\": \"A\", \"gnomad.exome.eas_kor\": \"5.15977e-01\", \"dbsnp\": \"rs1801243\", \"af_1000g_sas\": \"0.3681\", \"mutationtaster.score\": \"1&1&1&1&1&1&1\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"C\", \"cadd.pred\": \"11.79\", \"sift.pred\": \"tolerated\", \"spliceai_ds_max\": \"0.01\", \"gnomad.total\": \"0.441684173046\", \"genotype\": \"1/1\", \"intervar.class\": \"Benign\", \"krgdb_af\": \"0.514091\", \"clinvar.updated_class\": \"Benign\", \"wes300_af\": \"0.52167\", \"hgmd.web.literature\": \"{1. Huster (2012) Gastroenterology 142: 947 PubMed: 22240481 Diverse functional properties of Wilson disease ATP7B variants. | Primary literature report | fp:original reference supporting inclusion | Mild effect. functional.}|{2. Wu (2001) Arch Neurol 58: 971 PubMed: 11405812 Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in chinese patients with Wilson disease. | Additional literature report | dmq:additional reference not conclusive | probable polymorphism in Table 2.}|{3. Simsek Papur (2013) Eur J Med Genet 56: 175 PubMed: 23333878 Mutation analysis of ATP7B gene in Turkish Wilson disease patients: Identification of five novel mutations. | Additional literature report | dmq:additional reference not conclusive | Described as polymorphism}|{4. Squitti (2013) Neuromolecular Med 15: 515 PubMed: 23760784 ATP7B Variants as Modulators of Copper Dyshomeostasis in Alzheimer's Disease. | Functional characterisation | fp:additional reference supporting inclusion | Decreased ceruloplasmin and copper levels (T allele)}|{5. Abouelhoda (2016) Genome Biol 17: 235 PubMed: 27884173 Revisiting the morbid genome of Mendelian disorders. | Additional literature report | dm:additional reference not supporting inclusion | Reclassified as benign. Table S1 and S5}\", \"intervar.evidence.bv\": \"BA1&BS1&BP4&BP6\", \"strand\": \"false\", \"sift.score\": \"0.79\", \"wes_als312_af\": \"0.47917\", \"clinvar.class\": \"Benign\", \"ge_class\": \"Green\", \"exon_in_hgmd\": \"[\\\"2/21\\\"]\", \"chrom\": \"chr13\", \"gnomad.exome.sas\": \"3.51905e-01\", \"codon\": \"Tct/Gct\", \"mim.inheritance\": \"[\\\"AR\\\"]\", \"create_at\": \"2021-12-07T00:49:12.531\", \"exon\": \"[\\\"2/19\\\",\\\"2/21\\\",\\\"2/17\\\",\\\"3/22\\\",\\\"2/20\\\"]\"}"
    val BV2 = "{\"hgmd.mut\": \"ALT\", \"ge_green\": \"White matter disorders - childhood onset | Structural basal ganglia disorders | Severe Paediatric Disorders | Neonatal cholestasis | Iron metabolism disorders | Childhood onset dystonia or chorea or related movement disorder | Adult onset movement disorder | Brain channelopathy | Early onset dystonia | Hereditary ataxia - adult onset | Hypotonic infant | Inborn errors of metabolism | Neurodegenerative disorders - adult onset | Paediatric disorders | Undiagnosed metabolic disorders\", \"af_1000g_eas\": \"0.4841\", \"hgvsc\": \"[\\\"NM_001330579.2:c.1366G>C\\\",\\\"NM_000053.4:c.1366G>C\\\",\\\"NM_001005918.3:c.1366G>C\\\",\\\"NM_001243182.1:c.1033G>C\\\",\\\"NM_001330578.1:c.1366G>C\\\"]\", \"cadd.raw\": \"0.493883\", \"vaf\": \"1.0\", \"hgvsp\": \"[\\\"p.Val456Leu\\\",\\\"p.Val456Leu\\\",\\\"p.Val456Leu\\\",\\\"p.Val345Leu\\\",\\\"p.Val456Leu\\\"]\", \"gnomad.genome.eas\": \"4.66026e-01\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"gene.refgene\": \"ATP7B\", \"lrt.score\": \"0.761497\", \"exac.eas\": \"0.483\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\", \"tags\": \"[\\\"all\\\"]\", \"hgmd.tag\": \"DFP\", \"hgmd.pmid\": \"23830383\", \"polyphen.pred\": \"benign\", \"insilico_sanger\": \"Y\", \"polyphen.score\": \"0\", \"hgmd.hgvsp\": \"[\\\"p.Val456Leu\\\"]\", \"effect_level\": \"MED\", \"clinvar.clndbn\": \"[\\\"Wilson_disease&not_specified\\\"]\", \"fathmm.pred\": \"D&D&D&D&.&D\", \"pos\": \"52544805\", \"lrt.pred\": \"N\", \"ge_amber\": \"Cholestasis | Rare genetic inflammatory skin disorders\", \"hgmd.hgvsc\": \"[\\\"NM_000053.4:c.1366G>C\\\"]\", \"clinvar.updated_review\": \"criteria provided, multiple submitters, no conflicts\", \"gnomad.exome.eas\": \"4.83480e-01\", \"exac.sas\": \"0.347\", \"fathmm.score\": \"-3.8&-3.74&-3.93&-3.8&.&-3.82\", \"clinvar.id\": \"35702\", \"mim.disease\": \"Wilson disease, 277900 (3), Autosomal recessive\", \"hgmd.web.tag\": \"DFP\", \"sample\": \"21GMD048_20210525-171-5184_ATP7B-22_M\", \"disease_description\": \"DISEASE: Wilson disease (WD) [MIM:277900]: An autosomal recessive disorder of copper metabolism in which copper cannot be incorporated into ceruloplasmin in liver, and cannot be excreted from the liver into the bile. Copper accumulates in the liver and subsequently in the brain and kidney. The disease is characterized by neurologic manifestations and signs of cirrhosis. {ECO:0000269|PubMed:10051024, ECO:0000269|PubMed:10194254, ECO:0000269|PubMed:10447265, ECO:0000269|PubMed:10453196, ECO:0000269|PubMed:10502776, ECO:0000269|PubMed:10502777, ECO:0000269|PubMed:10544227, ECO:0000269|PubMed:10721669, ECO:0000269|PubMed:10790207, ECO:0000269|PubMed:10942420, ECO:0000269|PubMed:11043508, ECO:0000269|PubMed:11093740, ECO:0000269|PubMed:11180609, ECO:0000269|PubMed:11216666, ECO:0000269|PubMed:11231950, ECO:0000269|PubMed:11243728, ECO:0000269|PubMed:11405812, ECO:0000269|PubMed:11690702, ECO:0000269|PubMed:11954751, ECO:0000269|PubMed:12325021, ECO:0000269|PubMed:12376745, ECO:0000269|PubMed:12544487, ECO:0000269|PubMed:14639035, ECO:0000269|PubMed:14966923, ECO:0000269|PubMed:14986826, ECO:0000269|PubMed:15024742, ECO:0000269|PubMed:15557537, ECO:0000269|PubMed:15811015, ECO:0000269|PubMed:15845031, ECO:0000269|PubMed:15952988, ECO:0000269|PubMed:15967699, ECO:0000269|PubMed:16088907, ECO:0000269|PubMed:16207219, ECO:0000269|PubMed:16283883, ECO:0000269|PubMed:16649058, ECO:0000269|PubMed:17718866, ECO:0000269|PubMed:17823867, ECO:0000269|PubMed:17919502, ECO:0000269|PubMed:17949296, ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:18373411, ECO:0000269|PubMed:19033537, ECO:0000269|PubMed:20333758, ECO:0000269|PubMed:21398519, ECO:0000269|PubMed:21454443, ECO:0000269|PubMed:21645214, ECO:0000269|PubMed:21682854, ECO:0000269|PubMed:22075048, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:22484412, ECO:0000269|PubMed:22763723, ECO:0000269|PubMed:23159873, ECO:0000269|PubMed:23235335, ECO:0000269|PubMed:23275100, ECO:0000269|PubMed:23333878, ECO:0000269|PubMed:23518715, ECO:0000269|PubMed:23962630, ECO:0000269|PubMed:24476933, ECO:0000269|PubMed:24555712, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:25704634, ECO:0000269|PubMed:25982861, ECO:0000269|PubMed:26004889, ECO:0000269|PubMed:28856630, ECO:0000269|PubMed:7626145, ECO:0000269|PubMed:8298641, ECO:0000269|PubMed:8533760, ECO:0000269|PubMed:8782057, ECO:0000269|PubMed:8931691, ECO:0000269|PubMed:8938442, ECO:0000269|PubMed:8980283, ECO:0000269|PubMed:9222767, ECO:0000269|PubMed:9311736, ECO:0000269|PubMed:9452121, ECO:0000269|PubMed:9482578, ECO:0000269|PubMed:9554743, ECO:0000269|PubMed:9671269, ECO:0000269|PubMed:9772425, ECO:0000269|PubMed:9829905, ECO:0000269|PubMed:9837819, ECO:0000269|PubMed:9887381}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"hgmd.codon.disease\": \"_association_with\", \"filter\": \"PASS\", \"depth\": \"85\", \"qual\": \"2869.06\", \"snv\": \"hg19:13:052544805:C:G\", \"function_description\": \"FUNCTION: Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}.; \", \"mutationtaster.pred\": \"P&P&P&P&P&P&P\", \"reference\": \"hg19\", \"ref\": \"C\", \"gnomad.exome.eas_kor\": \"4.71189e-01\", \"dbsnp\": \"rs1801244\", \"af_1000g_sas\": \"0.362\", \"mutationtaster.score\": \"1&1&1&1&1&1&1\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"G\", \"cadd.pred\": \"7.568\", \"sift.pred\": \"tolerated\", \"spliceai_ds_max\": \"0.09\", \"gnomad.total\": \"0.437698735224\", \"genotype\": \"1/1\", \"intervar.class\": \"Benign\", \"krgdb_af\": \"0.471364\", \"clinvar.updated_class\": \"Benign\", \"wes300_af\": \"0.45\", \"hgmd.web.literature\": \"{1. Liu (2013) J Biol Regul Homeost Agents 27: 319 PubMed: 23830383 Genetic variability in copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with Alzheimer's disease in a Chinese population. | Primary literature report | fp:original reference supporting inclusion | No comments}|{2. Huster (2012) Gastroenterology 142: 947 PubMed: 22240481 Diverse functional properties of Wilson disease ATP7B variants. | Functional characterisation | fp:additional reference supporting inclusion | Partially impaired copper transport.}|{3. Liu (2015) Arch Med Res 46: 164 PubMed: 25704634 Genetic and Clinical Analysis in a Cohort of Patients with Wilson's Disease in Southwestern China. | Additional phenotype | dmq:additional reference not conclusive | Wilson disease ?}|{4. Cheng (2017) Clin Genet 92: 69 PubMed: 27982432 Spectrum of ATP7B mutations and genotype-phenotype correlation in large-scale Chinese patients with Wilson Disease. | Additional phenotype | fp:additional reference supporting inclusion | Wilson disease}\", \"intervar.evidence.bv\": \"BA1&BS1&BP4&BP6\", \"strand\": \"false\", \"sift.score\": \"0.45\", \"wes_als312_af\": \"0.42308\", \"clinvar.class\": \"Benign\", \"ge_class\": \"Green\", \"exon_in_hgmd\": \"[\\\"3/21\\\"]\", \"chrom\": \"chr13\", \"gnomad.exome.sas\": \"3.47245e-01\", \"codon\": \"Gtg/Ctg\", \"mim.inheritance\": \"[\\\"AR\\\"]\", \"create_at\": \"2021-12-07T00:49:12.531\", \"exon\": \"[\\\"3/19\\\",\\\"3/21\\\",\\\"3/17\\\",\\\"4/22\\\",\\\"3/20\\\"]\"}"
    val BV3 = "{\"hgmd.mut\": \"ALT\", \"ge_green\": \"White matter disorders - childhood onset | Structural basal ganglia disorders | Severe Paediatric Disorders | Neonatal cholestasis | Iron metabolism disorders | Childhood onset dystonia or chorea or related movement disorder | Adult onset movement disorder | Brain channelopathy | Early onset dystonia | Hereditary ataxia - adult onset | Hypotonic infant | Inborn errors of metabolism | Neurodegenerative disorders - adult onset | Paediatric disorders | Undiagnosed metabolic disorders\", \"af_1000g_eas\": \"0.4008\", \"hgvsc\": \"[\\\"NM_001330579.2:c.2243A>G\\\",\\\"NM_000053.4:c.2495A>G\\\",\\\"NM_001005918.3:c.2009A>G\\\",\\\"NM_001243182.1:c.2162A>G\\\",\\\"NM_001330578.1:c.2261A>G\\\"]\", \"cadd.raw\": \"3.506597\", \"vaf\": \"1.0\", \"hgvsp\": \"[\\\"p.Lys748Arg\\\",\\\"p.Lys832Arg\\\",\\\"p.Lys670Arg\\\",\\\"p.Lys721Arg\\\",\\\"p.Lys754Arg\\\"]\", \"gnomad.genome.eas\": \"3.85161e-01\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"gene.refgene\": \"ATP7B\", \"lrt.score\": \"0.000000\", \"exac.eas\": \"0.394\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\", \"tags\": \"[\\\"all\\\"]\", \"hgmd.tag\": \"DFP\", \"intervar.evidence.pv\": \"PM1\", \"hgmd.pmid\": \"21760992\", \"polyphen.pred\": \"benign\", \"insilico_sanger\": \"Y\", \"polyphen.score\": \"0.14\", \"hgmd.hgvsp\": \"[\\\"p.Lys832Arg\\\"]\", \"effect_level\": \"MED\", \"clinvar.clndbn\": \"[\\\"Wilson_disease&not_specified\\\"]\", \"fathmm.pred\": \"D&D&D&D&.&D\", \"pos\": \"52524488\", \"lrt.pred\": \"D\", \"ge_amber\": \"Cholestasis | Rare genetic inflammatory skin disorders\", \"hgmd.hgvsc\": \"[\\\"NM_000053.4:c.2495A>G\\\"]\", \"clinvar.updated_review\": \"criteria provided, multiple submitters, no conflicts\", \"gnomad.exome.eas\": \"3.96072e-01\", \"exac.sas\": \"0.514\", \"fathmm.score\": \"-2.64&-2.64&-2.64&-2.64&.&-2.64\", \"clinvar.id\": \"35707\", \"mim.disease\": \"Wilson disease, 277900 (3), Autosomal recessive\", \"hgmd.web.tag\": \"DFP\", \"sample\": \"21GMD048_20210525-171-5184_ATP7B-22_M\", \"disease_description\": \"DISEASE: Wilson disease (WD) [MIM:277900]: An autosomal recessive disorder of copper metabolism in which copper cannot be incorporated into ceruloplasmin in liver, and cannot be excreted from the liver into the bile. Copper accumulates in the liver and subsequently in the brain and kidney. The disease is characterized by neurologic manifestations and signs of cirrhosis. {ECO:0000269|PubMed:10051024, ECO:0000269|PubMed:10194254, ECO:0000269|PubMed:10447265, ECO:0000269|PubMed:10453196, ECO:0000269|PubMed:10502776, ECO:0000269|PubMed:10502777, ECO:0000269|PubMed:10544227, ECO:0000269|PubMed:10721669, ECO:0000269|PubMed:10790207, ECO:0000269|PubMed:10942420, ECO:0000269|PubMed:11043508, ECO:0000269|PubMed:11093740, ECO:0000269|PubMed:11180609, ECO:0000269|PubMed:11216666, ECO:0000269|PubMed:11231950, ECO:0000269|PubMed:11243728, ECO:0000269|PubMed:11405812, ECO:0000269|PubMed:11690702, ECO:0000269|PubMed:11954751, ECO:0000269|PubMed:12325021, ECO:0000269|PubMed:12376745, ECO:0000269|PubMed:12544487, ECO:0000269|PubMed:14639035, ECO:0000269|PubMed:14966923, ECO:0000269|PubMed:14986826, ECO:0000269|PubMed:15024742, ECO:0000269|PubMed:15557537, ECO:0000269|PubMed:15811015, ECO:0000269|PubMed:15845031, ECO:0000269|PubMed:15952988, ECO:0000269|PubMed:15967699, ECO:0000269|PubMed:16088907, ECO:0000269|PubMed:16207219, ECO:0000269|PubMed:16283883, ECO:0000269|PubMed:16649058, ECO:0000269|PubMed:17718866, ECO:0000269|PubMed:17823867, ECO:0000269|PubMed:17919502, ECO:0000269|PubMed:17949296, ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:18373411, ECO:0000269|PubMed:19033537, ECO:0000269|PubMed:20333758, ECO:0000269|PubMed:21398519, ECO:0000269|PubMed:21454443, ECO:0000269|PubMed:21645214, ECO:0000269|PubMed:21682854, ECO:0000269|PubMed:22075048, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:22484412, ECO:0000269|PubMed:22763723, ECO:0000269|PubMed:23159873, ECO:0000269|PubMed:23235335, ECO:0000269|PubMed:23275100, ECO:0000269|PubMed:23333878, ECO:0000269|PubMed:23518715, ECO:0000269|PubMed:23962630, ECO:0000269|PubMed:24476933, ECO:0000269|PubMed:24555712, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:25704634, ECO:0000269|PubMed:25982861, ECO:0000269|PubMed:26004889, ECO:0000269|PubMed:28856630, ECO:0000269|PubMed:7626145, ECO:0000269|PubMed:8298641, ECO:0000269|PubMed:8533760, ECO:0000269|PubMed:8782057, ECO:0000269|PubMed:8931691, ECO:0000269|PubMed:8938442, ECO:0000269|PubMed:8980283, ECO:0000269|PubMed:9222767, ECO:0000269|PubMed:9311736, ECO:0000269|PubMed:9452121, ECO:0000269|PubMed:9482578, ECO:0000269|PubMed:9554743, ECO:0000269|PubMed:9671269, ECO:0000269|PubMed:9772425, ECO:0000269|PubMed:9829905, ECO:0000269|PubMed:9837819, ECO:0000269|PubMed:9887381}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"hgmd.codon.disease\": \"_association_with\", \"filter\": \"PASS\", \"depth\": \"101\", \"qual\": \"3354.06\", \"snv\": \"hg19:13:052524488:T:C\", \"function_description\": \"FUNCTION: Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}.; \", \"mutationtaster.pred\": \"P&P&P&P&P&P&P\", \"reference\": \"hg19\", \"ref\": \"T\", \"gnomad.exome.eas_kor\": \"4.09067e-01\", \"dbsnp\": \"rs1061472\", \"af_1000g_sas\": \"0.5358\", \"mutationtaster.score\": \"1.949e-05&3.23647e-05&3.35011e-06&1.90271e-06&3.35011e-06&3.35011e-06&8.29391e-31\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"C\", \"cadd.pred\": \"24.3\", \"sift.pred\": \"tolerated\", \"spliceai_ds_max\": \"0.01\", \"gnomad.total\": \"0.539808315816\", \"genotype\": \"1/1\", \"intervar.class\": \"Benign\", \"krgdb_af\": \"0.39\", \"clinvar.updated_class\": \"Benign\", \"wes300_af\": \"0.20333\", \"hgmd.web.literature\": \"{1. Bucossi (2011) Int J Alzheimers Dis 2011: 973692 PubMed: 21760992 Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. | Primary literature report | fp:original reference supporting inclusion | No comments}|{2. Bucossi (2012) J Alzheimers Dis 29: 913 PubMed: 22356903 Association of K832R and R952K SNPs of Wilson's disease gene with Alzheimer's disease. | Additional literature report | . | None}|{3. Huster (2012) Gastroenterology 142: 947 PubMed: 22240481 Diverse functional properties of Wilson disease ATP7B variants. | Functional characterisation | fp:additional reference supporting inclusion | Partially impaired copper transport}|{4. Schushan (2012) Metallomics 4: 669 PubMed: 22692182 A structural model of the copper ATPase ATP7B to facilitate analysis of Wilson disease-causing mutations and studies of the transport mechanism. | Additional literature report | dmq:additional reference not conclusive | Structural modelling\", \"intervar.evidence.bv\": \"BA1&BS1&BP6\", \"strand\": \"false\", \"sift.score\": \"0.07\", \"wes_als312_af\": \"0.35737\", \"clinvar.class\": \"Benign\", \"ge_class\": \"Green\", \"exon_in_hgmd\": \"[\\\"10/21\\\"]\", \"chrom\": \"chr13\", \"gnomad.exome.sas\": \"5.10133e-01\", \"codon\": \"aAg/aGg\", \"mim.inheritance\": \"[\\\"AR\\\"]\", \"create_at\": \"2021-12-07T00:49:12.531\", \"exon\": \"[\\\"8/19\\\",\\\"10/21\\\",\\\"7/17\\\",\\\"11/22\\\",\\\"9/20\\\"]\"}"
    val BV4 = "{\"hgmd.mut\": \"ALT\", \"ge_green\": \"White matter disorders - childhood onset | Structural basal ganglia disorders | Severe Paediatric Disorders | Neonatal cholestasis | Iron metabolism disorders | Childhood onset dystonia or chorea or related movement disorder | Adult onset movement disorder | Brain channelopathy | Early onset dystonia | Hereditary ataxia - adult onset | Hypotonic infant | Inborn errors of metabolism | Neurodegenerative disorders - adult onset | Paediatric disorders | Undiagnosed metabolic disorders\", \"af_1000g_eas\": \"0.4018\", \"hgvsc\": \"[\\\"NM_001330579.2:c.2603G>A\\\",\\\"NM_000053.4:c.2855G>A\\\",\\\"NM_001005918.3:c.2244+335G>A\\\",\\\"NM_001243182.1:c.2522G>A\\\",\\\"NM_001330578.1:c.2621G>A\\\"]\", \"cadd.raw\": \"1.975787\", \"vaf\": \"0.990566037736\", \"hgvsp\": \"[\\\"p.Arg868Lys\\\",\\\"p.Arg952Lys\\\",\\\"\\\",\\\"p.Arg841Lys\\\",\\\"p.Arg874Lys\\\"]\", \"gnomad.genome.eas\": \"3.87887e-01\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"gene.refgene\": \"ATP7B\", \"lrt.score\": \"0.000000\", \"exac.eas\": \"0.394\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\", \"tags\": \"[\\\"all\\\"]\", \"hgmd.tag\": \"DP\", \"intervar.evidence.pv\": \"PM1\", \"hgmd.pmid\": \"22356903\", \"polyphen.pred\": \"benign\", \"insilico_sanger\": \"Y\", \"polyphen.score\": \"0\", \"hgmd.hgvsp\": \"[\\\"p.Arg952Lys\\\"]\", \"effect_level\": \"MED\", \"clinvar.clndbn\": \"[\\\"Wilson_disease&not_specified\\\"]\", \"fathmm.pred\": \"D&D&D&D&.&D\", \"pos\": \"52523808\", \"lrt.pred\": \"N\", \"ge_amber\": \"Cholestasis | Rare genetic inflammatory skin disorders\", \"hgmd.hgvsc\": \"[\\\"NM_000053.4:c.2855G>A\\\"]\", \"clinvar.updated_review\": \"criteria provided, multiple submitters, no conflicts\", \"gnomad.exome.eas\": \"3.96272e-01\", \"exac.sas\": \"0.527\", \"fathmm.score\": \"-3.79&-3.73&-3.78&-4.18&.&-3.85\", \"clinvar.id\": \"35708\", \"mim.disease\": \"Wilson disease, 277900 (3), Autosomal recessive\", \"hgmd.web.tag\": \"DP\", \"sample\": \"21GMD048_20210525-171-5184_ATP7B-22_M\", \"disease_description\": \"DISEASE: Wilson disease (WD) [MIM:277900]: An autosomal recessive disorder of copper metabolism in which copper cannot be incorporated into ceruloplasmin in liver, and cannot be excreted from the liver into the bile. Copper accumulates in the liver and subsequently in the brain and kidney. The disease is characterized by neurologic manifestations and signs of cirrhosis. {ECO:0000269|PubMed:10051024, ECO:0000269|PubMed:10194254, ECO:0000269|PubMed:10447265, ECO:0000269|PubMed:10453196, ECO:0000269|PubMed:10502776, ECO:0000269|PubMed:10502777, ECO:0000269|PubMed:10544227, ECO:0000269|PubMed:10721669, ECO:0000269|PubMed:10790207, ECO:0000269|PubMed:10942420, ECO:0000269|PubMed:11043508, ECO:0000269|PubMed:11093740, ECO:0000269|PubMed:11180609, ECO:0000269|PubMed:11216666, ECO:0000269|PubMed:11231950, ECO:0000269|PubMed:11243728, ECO:0000269|PubMed:11405812, ECO:0000269|PubMed:11690702, ECO:0000269|PubMed:11954751, ECO:0000269|PubMed:12325021, ECO:0000269|PubMed:12376745, ECO:0000269|PubMed:12544487, ECO:0000269|PubMed:14639035, ECO:0000269|PubMed:14966923, ECO:0000269|PubMed:14986826, ECO:0000269|PubMed:15024742, ECO:0000269|PubMed:15557537, ECO:0000269|PubMed:15811015, ECO:0000269|PubMed:15845031, ECO:0000269|PubMed:15952988, ECO:0000269|PubMed:15967699, ECO:0000269|PubMed:16088907, ECO:0000269|PubMed:16207219, ECO:0000269|PubMed:16283883, ECO:0000269|PubMed:16649058, ECO:0000269|PubMed:17718866, ECO:0000269|PubMed:17823867, ECO:0000269|PubMed:17919502, ECO:0000269|PubMed:17949296, ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:18373411, ECO:0000269|PubMed:19033537, ECO:0000269|PubMed:20333758, ECO:0000269|PubMed:21398519, ECO:0000269|PubMed:21454443, ECO:0000269|PubMed:21645214, ECO:0000269|PubMed:21682854, ECO:0000269|PubMed:22075048, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:22484412, ECO:0000269|PubMed:22763723, ECO:0000269|PubMed:23159873, ECO:0000269|PubMed:23235335, ECO:0000269|PubMed:23275100, ECO:0000269|PubMed:23333878, ECO:0000269|PubMed:23518715, ECO:0000269|PubMed:23962630, ECO:0000269|PubMed:24476933, ECO:0000269|PubMed:24555712, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:25704634, ECO:0000269|PubMed:25982861, ECO:0000269|PubMed:26004889, ECO:0000269|PubMed:28856630, ECO:0000269|PubMed:7626145, ECO:0000269|PubMed:8298641, ECO:0000269|PubMed:8533760, ECO:0000269|PubMed:8782057, ECO:0000269|PubMed:8931691, ECO:0000269|PubMed:8938442, ECO:0000269|PubMed:8980283, ECO:0000269|PubMed:9222767, ECO:0000269|PubMed:9311736, ECO:0000269|PubMed:9452121, ECO:0000269|PubMed:9482578, ECO:0000269|PubMed:9554743, ECO:0000269|PubMed:9671269, ECO:0000269|PubMed:9772425, ECO:0000269|PubMed:9829905, ECO:0000269|PubMed:9837819, ECO:0000269|PubMed:9887381}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"hgmd.codon.disease\": \"_association_with\", \"filter\": \"PASS\", \"depth\": \"106\", \"qual\": \"3401.06\", \"snv\": \"hg19:13:052523808:C:T\", \"function_description\": \"FUNCTION: Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}.; \", \"mutationtaster.pred\": \"P&P&P&P&P&P&P\", \"reference\": \"hg19\", \"ref\": \"C\", \"gnomad.exome.eas_kor\": \"4.09377e-01\", \"dbsnp\": \"rs732774\", \"af_1000g_sas\": \"0.5399\", \"mutationtaster.score\": \"0.999977&0.999595&0.999946&0.999946&0.999946&0.999946&1.72792e-29\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"T\", \"cadd.pred\": \"19.52\", \"sift.pred\": \"tolerated\", \"spliceai_ds_max\": \"0.08\", \"gnomad.total\": \"0.566639323799\", \"genotype\": \"1/1\", \"intervar.class\": \"Benign\", \"krgdb_af\": \"0.392727\", \"clinvar.updated_class\": \"Benign\", \"wes300_af\": \"0.20667\", \"hgmd.web.literature\": \"{2. Schushan (2012) Metallomics 4: 669 PubMed: 22692182 A structural model of the copper ATPase ATP7B to facilitate analysis of Wilson disease-causing mutations and studies of the transport mechanism. | Additional literature report | dm:additional reference not supporting inclusion | Structural modelling\", \"intervar.evidence.bv\": \"BA1&BS1&BP6\", \"strand\": \"false\", \"sift.score\": \"1\", \"wes_als312_af\": \"0.35897\", \"clinvar.class\": \"Benign\", \"ge_class\": \"Green\", \"exon_in_hgmd\": \"[\\\"12/21\\\"]\", \"chrom\": \"chr13\", \"gnomad.exome.sas\": \"5.21866e-01\", \"codon\": \"aGa/aAa\", \"mim.inheritance\": \"[\\\"AR\\\"]\", \"create_at\": \"2021-12-07T00:49:12.531\", \"exon\": \"[\\\"10/19\\\",\\\"12/21\\\",\\\"\\\",\\\"13/22\\\",\\\"11/20\\\"]\"}"
    val BV5 = "{\"hgmd.mut\": \"ALT\", \"ge_green\": \"White matter disorders - childhood onset | Structural basal ganglia disorders | Severe Paediatric Disorders | Neonatal cholestasis | Iron metabolism disorders | Childhood onset dystonia or chorea or related movement disorder | Adult onset movement disorder | Brain channelopathy | Early onset dystonia | Hereditary ataxia - adult onset | Hypotonic infant | Inborn errors of metabolism | Neurodegenerative disorders - adult onset | Paediatric disorders | Undiagnosed metabolic disorders\", \"af_1000g_eas\": \"0.4008\", \"hgvsc\": \"[\\\"NM_001330579.2:c.3167T>C\\\",\\\"NM_000053.4:c.3419T>C\\\",\\\"NM_001005918.3:c.2798T>C\\\",\\\"NM_001243182.1:c.3086T>C\\\",\\\"NM_001330578.1:c.3185T>C\\\"]\", \"cadd.raw\": \"1.641444\", \"vaf\": \"0.986666666667\", \"hgvsp\": \"[\\\"p.Val1056Ala\\\",\\\"p.Val1140Ala\\\",\\\"p.Val933Ala\\\",\\\"p.Val1029Ala\\\",\\\"p.Val1062Ala\\\"]\", \"gnomad.genome.eas\": \"3.89535e-01\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"gene.refgene\": \"ATP7B\", \"lrt.score\": \"0.057420\", \"exac.eas\": \"0.394\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\", \"tags\": \"[\\\"all\\\"]\", \"hgmd.tag\": \"DP\", \"intervar.evidence.pv\": \"PM1\", \"hgmd.pmid\": \"14966923\", \"polyphen.pred\": \"benign\", \"insilico_sanger\": \"Y\", \"polyphen.score\": \"0\", \"hgmd.hgvsp\": \"[\\\"p.Val1140Ala\\\"]\", \"effect_level\": \"MED\", \"clinvar.clndbn\": \"[\\\"Wilson_disease&not_specified\\\"]\", \"fathmm.pred\": \"D&D&D&D&D&.&D\", \"pos\": \"52515354\", \"lrt.pred\": \"N\", \"ge_amber\": \"Cholestasis | Rare genetic inflammatory skin disorders\", \"hgmd.hgvsc\": \"[\\\"NM_000053.4:c.3419T>C\\\"]\", \"clinvar.updated_review\": \"criteria provided, multiple submitters, no conflicts\", \"gnomad.exome.eas\": \"3.96807e-01\", \"exac.sas\": \"0.526\", \"fathmm.score\": \"-3.86&-3.78&-3.97&-3.84&-4.26&.&-3.87\", \"clinvar.id\": \"35720\", \"mim.disease\": \"Wilson disease, 277900 (3), Autosomal recessive\", \"hgmd.web.tag\": \"DP\", \"sample\": \"21GMD048_20210525-171-5184_ATP7B-22_M\", \"disease_description\": \"DISEASE: Wilson disease (WD) [MIM:277900]: An autosomal recessive disorder of copper metabolism in which copper cannot be incorporated into ceruloplasmin in liver, and cannot be excreted from the liver into the bile. Copper accumulates in the liver and subsequently in the brain and kidney. The disease is characterized by neurologic manifestations and signs of cirrhosis. {ECO:0000269|PubMed:10051024, ECO:0000269|PubMed:10194254, ECO:0000269|PubMed:10447265, ECO:0000269|PubMed:10453196, ECO:0000269|PubMed:10502776, ECO:0000269|PubMed:10502777, ECO:0000269|PubMed:10544227, ECO:0000269|PubMed:10721669, ECO:0000269|PubMed:10790207, ECO:0000269|PubMed:10942420, ECO:0000269|PubMed:11043508, ECO:0000269|PubMed:11093740, ECO:0000269|PubMed:11180609, ECO:0000269|PubMed:11216666, ECO:0000269|PubMed:11231950, ECO:0000269|PubMed:11243728, ECO:0000269|PubMed:11405812, ECO:0000269|PubMed:11690702, ECO:0000269|PubMed:11954751, ECO:0000269|PubMed:12325021, ECO:0000269|PubMed:12376745, ECO:0000269|PubMed:12544487, ECO:0000269|PubMed:14639035, ECO:0000269|PubMed:14966923, ECO:0000269|PubMed:14986826, ECO:0000269|PubMed:15024742, ECO:0000269|PubMed:15557537, ECO:0000269|PubMed:15811015, ECO:0000269|PubMed:15845031, ECO:0000269|PubMed:15952988, ECO:0000269|PubMed:15967699, ECO:0000269|PubMed:16088907, ECO:0000269|PubMed:16207219, ECO:0000269|PubMed:16283883, ECO:0000269|PubMed:16649058, ECO:0000269|PubMed:17718866, ECO:0000269|PubMed:17823867, ECO:0000269|PubMed:17919502, ECO:0000269|PubMed:17949296, ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:18373411, ECO:0000269|PubMed:19033537, ECO:0000269|PubMed:20333758, ECO:0000269|PubMed:21398519, ECO:0000269|PubMed:21454443, ECO:0000269|PubMed:21645214, ECO:0000269|PubMed:21682854, ECO:0000269|PubMed:22075048, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:22484412, ECO:0000269|PubMed:22763723, ECO:0000269|PubMed:23159873, ECO:0000269|PubMed:23235335, ECO:0000269|PubMed:23275100, ECO:0000269|PubMed:23333878, ECO:0000269|PubMed:23518715, ECO:0000269|PubMed:23962630, ECO:0000269|PubMed:24476933, ECO:0000269|PubMed:24555712, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:25704634, ECO:0000269|PubMed:25982861, ECO:0000269|PubMed:26004889, ECO:0000269|PubMed:28856630, ECO:0000269|PubMed:7626145, ECO:0000269|PubMed:8298641, ECO:0000269|PubMed:8533760, ECO:0000269|PubMed:8782057, ECO:0000269|PubMed:8931691, ECO:0000269|PubMed:8938442, ECO:0000269|PubMed:8980283, ECO:0000269|PubMed:9222767, ECO:0000269|PubMed:9311736, ECO:0000269|PubMed:9452121, ECO:0000269|PubMed:9482578, ECO:0000269|PubMed:9554743, ECO:0000269|PubMed:9671269, ECO:0000269|PubMed:9772425, ECO:0000269|PubMed:9829905, ECO:0000269|PubMed:9837819, ECO:0000269|PubMed:9887381}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"hgmd.codon.disease\": \"Wilson_disease\", \"filter\": \"PASS\", \"depth\": \"75\", \"qual\": \"2368.06\", \"snv\": \"hg19:13:052515354:A:G\", \"function_description\": \"FUNCTION: Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}.; \", \"mutationtaster.pred\": \"P&P&P&P&P&P&P\", \"reference\": \"hg19\", \"ref\": \"A\", \"gnomad.exome.eas_kor\": \"4.09591e-01\", \"dbsnp\": \"rs1801249\", \"af_1000g_sas\": \"0.5399\", \"mutationtaster.score\": \"1&1&1&1&1&1&1\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"G\", \"cadd.pred\": \"17.06\", \"sift.pred\": \"tolerated\", \"spliceai_ds_max\": \"0.01\", \"gnomad.total\": \"0.569697703573\", \"genotype\": \"1/1\", \"intervar.class\": \"Benign\", \"krgdb_af\": \"0.391818\", \"clinvar.updated_class\": \"Benign\", \"wes300_af\": \"0.415\", \"hgmd.web.literature\": \"{1. Liu (2004) World J Gastroenterol 10: 590 PubMed: 14966923 Correlation of ATP7B genotype with phenotype in Chinese patients with Wilson disease. | Primary literature report | fp:original reference supporting inclusion | compound het with V1106I. Late onset.}|{2. Wu (2001) Arch Neurol 58: 971 PubMed: 11405812 Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in chinese patients with Wilson disease. | Additional literature report | dm:additional reference not supporting inclusion | probable polymorphism in Table 2.}|{3. Davies (2008) Genet Test 12: 139 PubMed: 18373411 New mutations in the Wilson disease gene ATP7B: implications for molecular testing. | Additional literature report | dm:additional reference not supporting inclusion | Non-disease causing}|{4. Hsi (2008) Hum Mutat 29: 491 PubMed: 18203200 Sequence variation in the ATP-binding domain of the Wilson disease transporter ATP7B affects copper transport in a yeast model system. | Functional characterisation | dm:additional reference not supporting inclusion | Normal variant}|{5. 1000 Genomes Project (2010) Nature 467: 1061 PubMed: 20981092 A map of human genome variation from population-scale sequencing. | Additional literature report | dmq:additional reference not conclusive | Present in 1000 genomes data. Supplementary table 5}|{6. Bell (2011) Sci Transl Med 3: 65ra4 PubMed: 21228398 Carrier testing for severe childhood recessive diseases by next-generation sequencing. | Additional literature report | dm:additional reference not supporting inclusion | likely polymorphism. supplementary table 8.}|{7. Schushan (2012) Metallomics 4: 669 PubMed: 22692182 A structural model of the copper ATPase ATP7B to facilitate analysis of Wilson disease-causing mutations and studies of the transport mechanism. | Additional literature report | dm:additional reference not supporting inclusion | Structural modelling\", \"intervar.evidence.bv\": \"BA1&BS1&BP4&BP6\", \"strand\": \"false\", \"sift.score\": \"1\", \"wes_als312_af\": \"0.36058\", \"clinvar.class\": \"Benign\", \"ge_class\": \"Green\", \"exon_in_hgmd\": \"[\\\"16/21\\\"]\", \"chrom\": \"chr13\", \"gnomad.exome.sas\": \"5.21310e-01\", \"codon\": \"gTc/gCc\", \"mim.inheritance\": \"[\\\"AR\\\"]\", \"create_at\": \"2021-12-07T00:49:12.531\", \"exon\": \"[\\\"14/19\\\",\\\"16/21\\\",\\\"12/17\\\",\\\"17/22\\\",\\\"15/20\\\"]\"}"
    val BV6 = "{\"hgmd.mut\": \"REF\", \"ge_green\": \"White matter disorders - childhood onset | Structural basal ganglia disorders | Severe Paediatric Disorders | Neonatal cholestasis | Iron metabolism disorders | Childhood onset dystonia or chorea or related movement disorder | Adult onset movement disorder | Brain channelopathy | Early onset dystonia | Hereditary ataxia - adult onset | Hypotonic infant | Inborn errors of metabolism | Neurodegenerative disorders - adult onset | Paediatric disorders | Undiagnosed metabolic disorders\", \"af_1000g_eas\": \"0.4018\", \"hgvsc\": \"[\\\"NM_001330579.2:c.3651+6C>T\\\",\\\"NM_000053.4:c.3903+6C>T\\\",\\\"NM_001005918.3:c.3282+6C>T\\\",\\\"NM_001243182.1:c.3570+6C>T\\\",\\\"NM_001330578.1:c.3669+6C>T\\\"]\", \"ada_score\": \"3.00684534904205E-5\", \"vaf\": \"0.987179487179\", \"gnomad.genome.eas\": \"3.90039e-01\", \"so_term\": \"[\\\"splice_region_variant\\\",\\\"intron_variant\\\"]\", \"gene.refgene\": \"ATP7B\", \"exac.eas\": \"0.395\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:21GMD048:022\", \"tags\": \"[\\\"all\\\"]\", \"hgmd.tag\": \"DP\", \"hgmd.pmid\": \"17264425\", \"insilico_sanger\": \"Y\", \"effect_level\": \"MED\", \"clinvar.clndbn\": \"[\\\"Wilson_disease&not_specified&not_provided\\\"]\", \"pos\": \"52511606\", \"ge_amber\": \"Cholestasis | Rare genetic inflammatory skin disorders\", \"hgmd.hgvsc\": \"[\\\"NM_000053.4:c.3903+6C>T\\\"]\", \"clinvar.updated_review\": \"criteria provided, multiple submitters, no conflicts\", \"gnomad.exome.eas\": \"3.97674e-01\", \"exac.sas\": \"0.515\", \"clinvar.id\": \"35727\", \"rf_score\": \"0.0\", \"mim.disease\": \"Wilson disease, 277900 (3), Autosomal recessive\", \"hgmd.web.tag\": \"DM?\", \"sample\": \"21GMD048_20210525-171-5184_ATP7B-22_M\", \"disease_description\": \"DISEASE: Wilson disease (WD) [MIM:277900]: An autosomal recessive disorder of copper metabolism in which copper cannot be incorporated into ceruloplasmin in liver, and cannot be excreted from the liver into the bile. Copper accumulates in the liver and subsequently in the brain and kidney. The disease is characterized by neurologic manifestations and signs of cirrhosis. {ECO:0000269|PubMed:10051024, ECO:0000269|PubMed:10194254, ECO:0000269|PubMed:10447265, ECO:0000269|PubMed:10453196, ECO:0000269|PubMed:10502776, ECO:0000269|PubMed:10502777, ECO:0000269|PubMed:10544227, ECO:0000269|PubMed:10721669, ECO:0000269|PubMed:10790207, ECO:0000269|PubMed:10942420, ECO:0000269|PubMed:11043508, ECO:0000269|PubMed:11093740, ECO:0000269|PubMed:11180609, ECO:0000269|PubMed:11216666, ECO:0000269|PubMed:11231950, ECO:0000269|PubMed:11243728, ECO:0000269|PubMed:11405812, ECO:0000269|PubMed:11690702, ECO:0000269|PubMed:11954751, ECO:0000269|PubMed:12325021, ECO:0000269|PubMed:12376745, ECO:0000269|PubMed:12544487, ECO:0000269|PubMed:14639035, ECO:0000269|PubMed:14966923, ECO:0000269|PubMed:14986826, ECO:0000269|PubMed:15024742, ECO:0000269|PubMed:15557537, ECO:0000269|PubMed:15811015, ECO:0000269|PubMed:15845031, ECO:0000269|PubMed:15952988, ECO:0000269|PubMed:15967699, ECO:0000269|PubMed:16088907, ECO:0000269|PubMed:16207219, ECO:0000269|PubMed:16283883, ECO:0000269|PubMed:16649058, ECO:0000269|PubMed:17718866, ECO:0000269|PubMed:17823867, ECO:0000269|PubMed:17919502, ECO:0000269|PubMed:17949296, ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:18373411, ECO:0000269|PubMed:19033537, ECO:0000269|PubMed:20333758, ECO:0000269|PubMed:21398519, ECO:0000269|PubMed:21454443, ECO:0000269|PubMed:21645214, ECO:0000269|PubMed:21682854, ECO:0000269|PubMed:22075048, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:22484412, ECO:0000269|PubMed:22763723, ECO:0000269|PubMed:23159873, ECO:0000269|PubMed:23235335, ECO:0000269|PubMed:23275100, ECO:0000269|PubMed:23333878, ECO:0000269|PubMed:23518715, ECO:0000269|PubMed:23962630, ECO:0000269|PubMed:24476933, ECO:0000269|PubMed:24555712, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:25704634, ECO:0000269|PubMed:25982861, ECO:0000269|PubMed:26004889, ECO:0000269|PubMed:28856630, ECO:0000269|PubMed:7626145, ECO:0000269|PubMed:8298641, ECO:0000269|PubMed:8533760, ECO:0000269|PubMed:8782057, ECO:0000269|PubMed:8931691, ECO:0000269|PubMed:8938442, ECO:0000269|PubMed:8980283, ECO:0000269|PubMed:9222767, ECO:0000269|PubMed:9311736, ECO:0000269|PubMed:9452121, ECO:0000269|PubMed:9482578, ECO:0000269|PubMed:9554743, ECO:0000269|PubMed:9671269, ECO:0000269|PubMed:9772425, ECO:0000269|PubMed:9829905, ECO:0000269|PubMed:9837819, ECO:0000269|PubMed:9887381}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"hgmd.codon.disease\": \"Wilson_disease\", \"filter\": \"PASS\", \"depth\": \"78\", \"qual\": \"2601.06\", \"snv\": \"hg19:13:052511606:G:A\", \"function_description\": \"FUNCTION: Copper ion transmembrane transporter involved in the export of copper out of the cells. It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload. {ECO:0000269|PubMed:18203200, ECO:0000269|PubMed:22240481, ECO:0000269|PubMed:24706876, ECO:0000269|PubMed:26004889}.; \", \"reference\": \"hg19\", \"ref\": \"G\", \"gnomad.exome.eas_kor\": \"4.09067e-01\", \"dbsnp\": \"rs2282057\", \"af_1000g_sas\": \"0.5358\", \"splicing_distance\": \"6\", \"organism\": \"homo sapiens\", \"alt\": \"A\", \"spliceai_ds_max\": \"0.01\", \"gnomad.total\": \"0.538658049069\", \"genotype\": \"1/1\", \"krgdb_af\": \"0.387273\", \"clinvar.updated_class\": \"Benign/Likely benign\", \"wes300_af\": \"0.42333\", \"hgmd.web.literature\": \"{2. Thomas (1995) Nat Genet 9: 210 PubMed: 7626145 The Wilson disease gene: spectrum of mutations and their consequences. | Additional literature report | fp:additional reference not supporting inclusion | Found in normal samples\", \"strand\": \"false\", \"wes_als312_af\": \"0.35737\", \"clinvar.class\": \"Benign/Likely_benign\", \"ge_class\": \"Green\", \"chrom\": \"chr13\", \"gnomad.exome.sas\": \"5.10362e-01\", \"mim.inheritance\": \"[\\\"AR\\\"]\", \"create_at\": \"2021-12-07T00:49:12.531\"}"
    val S061LPV1 = "{\"hgmd.mut\": \"ALT\", \"hgvsc\": \"[\\\"NM_130804.2:c.196_200dup\\\",\\\"NM_000244.3:c.196_200dup\\\",\\\"NM_001370251.1:c.196_200dup\\\",\\\"NM_001370259.1:c.196_200dup\\\",\\\"NM_001370260.1:c.196_200dup\\\",\\\"NM_001370261.1:c.196_200dup\\\",\\\"NM_001370262.1:c.196_200dup\\\",\\\"NM_001370263.1:c.196_200dup\\\",\\\"NM_130799.2:c.196_200dup\\\",\\\"NM_130800.2:c.196_200dup\\\",\\\"NM_130801.2:c.196_200dup\\\",\\\"NM_130802.2:c.196_200dup\\\",\\\"NM_130803.2:c.196_200dup\\\"]\", \"reference\": \"hg19\", \"go.molecular_function\": \"[\\\"four-way junction DNA binding\\\",\\\"Y-form DNA binding\\\",\\\"chromatin binding\\\",\\\"double-stranded DNA binding\\\",\\\"protein binding\\\",\\\"histone-lysine N-methyltransferase activity\\\",\\\"protein binding, bridging\\\",\\\"transcription regulatory region DNA binding\\\",\\\"protein N-terminus binding\\\",\\\"R-SMAD binding\\\"]\", \"ref\": \"G\", \"gene.full_name\": \"menin 1\", \"vaf\": \"0.513605442177\", \"hgvsp\": \"[\\\"p.Asp70ProfsTer51\\\"]\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"essential_gene\": \"E\", \"so_term\": \"[\\\"frameshift_variant\\\"]\", \"alt\": \"GGGGCT\", \"gene.refgene\": \"MEN1\", \"spliceai_ds_max\": \"0\", \"analysis\": \"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\", \"p(hi)\": \"0.51278\", \"tags\": \"[\\\"all\\\",\\\"candidate\\\"]\", \"genotype\": \"0/1\", \"hgmd.tag\": \"DM\", \"krg_db_1100\": \"0\", \"hgmd.pmid\": \"9683585\", \"insilico_sanger\": \"Y\", \"hgmd.hgvsp\": \"[\\\"p.Asp70ProfsTer51\\\"]\", \"hgmd.web.literature\": \"{1. Giraud (1998) Am J Hum Genet 63: 455 PubMed: 9683585 Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. | Primary literature report | dm:original reference supporting inclusion | No comments},{2. Jeong (2014) Oncol Lett 8: 230 PubMed: 24959251 Multiple endocrine neoplasia type 1 associated with breast cancer: A case report and review of the literature. | Additional case report | dm:additional reference supporting inclusion | None}\", \"effect_level\": \"HIGH\", \"mim.phenotype_id\": \"[\\\"131100\\\"]\", \"strand\": \"false\", \"pos\": \"64577381\", \"mgi_mouse.gene\": \"Men1\", \"go.cellular_component\": \"[\\\"nuclear chromosome, telomeric region\\\",\\\"chromatin\\\",\\\"nuclear chromatin\\\",\\\"nucleus\\\",\\\"nucleoplasm\\\",\\\"cytoplasm\\\",\\\"endoplasmic reticulum lumen\\\",\\\"cytosol\\\",\\\"nuclear matrix\\\",\\\"cleavage furrow\\\",\\\"histone methyltransferase complex\\\",\\\"protein complex\\\"]\", \"hgmd.hgvsc\": \"[\\\"NM_130799.2:c.196_200dup\\\"]\", \"go.biological_process\": \"[\\\"negative regulation of transcription from RNA polymerase II promoter\\\",\\\"MAPK cascade\\\",\\\"mitotic cell cycle\\\",\\\"negative regulation of protein phosphorylation\\\",\\\"osteoblast development\\\",\\\"type B pancreatic cell differentiation\\\",\\\"DNA repair\\\",\\\"transcription, DNA-templated\\\",\\\"cellular response to DNA damage stimulus\\\",\\\"brain development\\\",\\\"negative regulation of cell proliferation\\\",\\\"response to UV\\\",\\\"response to gamma radiation\\\",\\\"negative regulation of cell-substrate adhesion\\\",\\\"positive regulation of transforming growth factor beta receptor signaling pathway\\\",\\\"positive regulation of protein binding\\\",\\\"regulation of activin receptor signaling pathway\\\",\\\"histone lysine methylation\\\",\\\"negative regulation of sequence-specific DNA binding transcription factor activity\\\",\\\"post-translational protein modification\\\",\\\"cellular protein metabolic process\\\",\\\"negative regulation of osteoblast differentiation\\\",\\\"negative regulation of cyclin-dependent protein serine/threonine kinase activity\\\",\\\"negative regulation of cell cycle\\\",\\\"negative regulation of transcription, DNA-templated\\\",\\\"positive regulation of transcription from RNA polymerase II promoter\\\",\\\"negative regulation of JNK cascade\\\",\\\"decidualization\\\",\\\"negative regulation of epithelial cell proliferation\\\",\\\"negative regulation of telomerase activity\\\",\\\"regulation of type B pancreatic cell proliferation\\\",\\\"cellular response to glucose stimulus\\\",\\\"cellular response to peptide hormone stimulus\\\",\\\"response to transforming growth factor beta\\\",\\\"negative regulation of cell cycle G1/S phase transition\\\",\\\"beta-catenin-TCF complex assembly\\\"]\", \"cancer2770_freq\": \"0\", \"mim.disease\": \"Angiofibroma, somatic (3) | Adrenal adenoma, somatic (3) | Parathyroid adenoma, somatic (3) | Lipoma, somatic (3) | Carcinoid tumor of lung (3) | Multiple endocrine neoplasia 1, 131100 (3), Autosomal dominant\", \"hgmd.web.tag\": \"DM\", \"mgi_mouse.phenotype\": \"homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; embryo phenotype; liver/biliary system phenotype; immune system phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (characteristics involving the ability of an organism to live and age normally throughout development and life span); reproductive system phenotype; neoplasm;\", \"exon_in_hgmd\": \"[\\\"2/10\\\"]\", \"sample\": \"21Cancer058_MEN1-03_20210622-171-5329\", \"disease_description\": \"DISEASE: Note=MEN1 inactivating mutations are responsible for hyperfunctioning of the parathyroid glands and subsequent primary hyperparathyroidism. Primary hyperparathyroidism can occur in isolation or in association with multiple endocrine neoplasia. {ECO:0000269|PubMed:10634381, ECO:0000269|PubMed:10664521, ECO:0000269|PubMed:12016470, ECO:0000269|PubMed:12699448, ECO:0000269|PubMed:9792884, ECO:0000269|PubMed:9843042, ECO:0000269|PubMed:9888389}.;\", \"chrom\": \"chr11\", \"filter\": \"PASS\", \"codon\": \"ccc/ccAGCCCc\", \"mim.inheritance\": \"[\\\"AD\\\"]\", \"depth\": \"588\", \"qual\": \"11767.7\", \"snv\": \"hg19:11:064577381:G:GGGGCT\", \"create_at\": \"2021-12-01T13:39:48.772\", \"exon\": \"[\\\"3/11\\\",\\\"2/10\\\",\\\"2/11\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\",\\\"2/10\\\"]\", \"trait_association(gwas)\": \"Urate levels[21768215];\", \"function_description\": \"FUNCTION: Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair. {ECO:0000250, ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12837246, ECO:0000269|PubMed:12874027, ECO:0000269|PubMed:14992727}.;\", \"class_order\": \"100\", \"class\": \"High_effect\"}"
    val S061BV1 = "{\"intervar_\": \"Benign\", \"hgvsc\": \"[\\\"NM_130804.2:c.1269C>T\\\",\\\"NM_000244.3:c.1269C>T\\\",\\\"\\\",\\\"NM_001370251.1:c.1380C>T\\\",\\\"NM_001370259.1:c.1254C>T\\\",\\\"NM_001370260.1:c.1254C>T\\\",\\\"NM_001370261.1:c.1254C>T\\\",\\\"NM_001370262.1:c.1149C>T\\\",\\\"NM_001370263.1:c.1149C>T\\\",\\\"\\\",\\\"NM_130799.2:c.1254C>T\\\",\\\"NM_130800.2:c.1269C>T\\\",\\\"NM_130801.2:c.1269C>T\\\",\\\"NM_130802.2:c.1269C>T\\\",\\\"NM_130803.2:c.1269C>T\\\"]\", \"go.molecular_function\": \"[\\\"four-way junction DNA binding\\\",\\\"Y-form DNA binding\\\",\\\"chromatin binding\\\",\\\"double-stranded DNA binding\\\",\\\"protein binding\\\",\\\"histone-lysine N-methyltransferase activity\\\",\\\"protein binding, bridging\\\",\\\"transcription regulatory region DNA binding\\\",\\\"protein N-terminus binding\\\",\\\"R-SMAD binding\\\"]\", \"gene.full_name\": \"menin 1\", \"vaf\": \"1\", \"intervar.evidence_\": \"BA1:1 BS1:1 BP4:1 BP6:1 BP7:1\", \"hgvsp\": \"[\\\"p.Asp423=\\\",\\\"p.Asp423=\\\",\\\"\\\",\\\"p.Asp460=\\\",\\\"p.Asp418=\\\",\\\"p.Asp418=\\\",\\\"p.Asp418=\\\",\\\"p.Asp383=\\\",\\\"p.Asp383=\\\",\\\"\\\",\\\"p.Asp418=\\\",\\\"p.Asp423=\\\",\\\"p.Asp423=\\\",\\\"p.Asp423=\\\",\\\"p.Asp423=\\\"]\", \"1000g\": \"0.307907\", \"essential_gene\": \"E\", \"gnomad.genome.eas\": \"0.3907\", \"so_term\": \"[\\\"synonymous_variant\\\"]\", \"gene.refgene\": \"MEN1\", \"gnomad.exome.all\": \"0.3930\", \"analysis\": \"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\", \"tags\": \"[\\\"all\\\"]\", \"krg_db_1100\": \"0.380909\", \"insilico_sanger\": \"Y\", \"esp6500.all\": \"0.3040\", \"hgmd.hgvsp\": \"[\\\"p.Asp418=\\\"]\", \"effect_level\": \"LOW\", \"clinvar.clndbn\": \"[\\\"Hyperparathyroidism\\\",\\\"Multiple_endocrine_neoplasia,_type_1\\\",\\\"Hereditary_cancer-predisposing_syndrome\\\",\\\"not_specified\\\",\\\"none_provided\\\"]\", \"pos\": \"64572602\", \"go.cellular_component\": \"[\\\"nuclear chromosome, telomeric region\\\",\\\"chromatin\\\",\\\"nuclear chromatin\\\",\\\"nucleus\\\",\\\"nucleoplasm\\\",\\\"cytoplasm\\\",\\\"endoplasmic reticulum lumen\\\",\\\"cytosol\\\",\\\"nuclear matrix\\\",\\\"cleavage furrow\\\",\\\"histone methyltransferase complex\\\",\\\"protein complex\\\"]\", \"hgmd.hgvsc\": \"[\\\"NM_130799.2:c.1254C>T\\\"]\", \"gnomad.exome.eas\": \"0.3849\", \"go.biological_process\": \"[\\\"negative regulation of transcription from RNA polymerase II promoter\\\",\\\"MAPK cascade\\\",\\\"mitotic cell cycle\\\",\\\"negative regulation of protein phosphorylation\\\",\\\"osteoblast development\\\",\\\"type B pancreatic cell differentiation\\\",\\\"DNA repair\\\",\\\"transcription, DNA-templated\\\",\\\"cellular response to DNA damage stimulus\\\",\\\"brain development\\\",\\\"negative regulation of cell proliferation\\\",\\\"response to UV\\\",\\\"response to gamma radiation\\\",\\\"negative regulation of cell-substrate adhesion\\\",\\\"positive regulation of transforming growth factor beta receptor signaling pathway\\\",\\\"positive regulation of protein binding\\\",\\\"regulation of activin receptor signaling pathway\\\",\\\"histone lysine methylation\\\",\\\"negative regulation of sequence-specific DNA binding transcription factor activity\\\",\\\"post-translational protein modification\\\",\\\"cellular protein metabolic process\\\",\\\"negative regulation of osteoblast differentiation\\\",\\\"negative regulation of cyclin-dependent protein serine/threonine kinase activity\\\",\\\"negative regulation of cell cycle\\\",\\\"negative regulation of transcription, DNA-templated\\\",\\\"positive regulation of transcription from RNA polymerase II promoter\\\",\\\"negative regulation of JNK cascade\\\",\\\"decidualization\\\",\\\"negative regulation of epithelial cell proliferation\\\",\\\"negative regulation of telomerase activity\\\",\\\"regulation of type B pancreatic cell proliferation\\\",\\\"cellular response to glucose stimulus\\\",\\\"cellular response to peptide hormone stimulus\\\",\\\"response to transforming growth factor beta\\\",\\\"negative regulation of cell cycle G1/S phase transition\\\",\\\"beta-catenin-TCF complex assembly\\\"]\", \"clinvar.id\": \"96249\", \"mim.disease\": \"Angiofibroma, somatic (3) | Adrenal adenoma, somatic (3) | Parathyroid adenoma, somatic (3) | Lipoma, somatic (3) | Carcinoid tumor of lung (3) | Multiple endocrine neoplasia 1, 131100 (3), Autosomal dominant\", \"sample\": \"21Cancer058_MEN1-03_20210622-171-5329\", \"disease_description\": \"DISEASE: Note=MEN1 inactivating mutations are responsible for hyperfunctioning of the parathyroid glands and subsequent primary hyperparathyroidism. Primary hyperparathyroidism can occur in isolation or in association with multiple endocrine neoplasia. {ECO:0000269|PubMed:10634381, ECO:0000269|PubMed:10664521, ECO:0000269|PubMed:12016470, ECO:0000269|PubMed:12699448, ECO:0000269|PubMed:9792884, ECO:0000269|PubMed:9843042, ECO:0000269|PubMed:9888389}.;\", \"filter\": \"PASS\", \"gnomad.genome.all\": \"0.3262\", \"depth\": \"462\", \"qual\": \"14765.8\", \"snv\": \"hg19:11:064572602:G:A\", \"trait_association(gwas)\": \"Urate levels[21768215];\", \"function_description\": \"FUNCTION: Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair. {ECO:0000250, ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12837246, ECO:0000269|PubMed:12874027, ECO:0000269|PubMed:14992727}.;\", \"reference\": \"hg19\", \"ref\": \"G\", \"dbsnp\": \"rs2071313\", \"exac.all\": \"0.3934\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"A\", \"spliceai_ds_max\": \"0\", \"p(hi)\": \"0.51278\", \"genotype\": \"1/1\", \"clinvar.updated_class\": \"Benign\", \"mim.phenotype_id\": \"[\\\"131100\\\"]\", \"strand\": \"false\", \"mgi_mouse.gene\": \"Men1\", \"clinvar.class\": \"Benign\", \"cancer2770_freq\": \"0.38917\", \"mgi_mouse.phenotype\": \"homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; embryo phenotype; liver/biliary system phenotype; immune system phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (characteristics involving the ability of an organism to live and age normally throughout development and life span); reproductive system phenotype; neoplasm;\", \"exon_in_hgmd\": \"[\\\"9/10\\\"]\", \"chrom\": \"chr11\", \"codon\": \"gaC/gaT\", \"mim.inheritance\": \"[\\\"AD\\\"]\", \"create_at\": \"2021-12-01T13:39:48.772\", \"exon\": \"[\\\"10/11\\\",\\\"9/10\\\",\\\"\\\",\\\"10/11\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\"]\"}"
    val S061BV2 = "{\"intervar_\": \"Benign\", \"hgvsc\": \"[\\\"NM_130804.2:c.1314T>C\\\",\\\"NM_000244.3:c.1314T>C\\\",\\\"\\\",\\\"NM_001370251.1:c.1425T>C\\\",\\\"NM_001370259.1:c.1299T>C\\\",\\\"NM_001370260.1:c.1299T>C\\\",\\\"NM_001370261.1:c.1299T>C\\\",\\\"NM_001370262.1:c.1194T>C\\\",\\\"NM_001370263.1:c.1194T>C\\\",\\\"\\\",\\\"NM_130799.2:c.1299T>C\\\",\\\"NM_130800.2:c.1314T>C\\\",\\\"NM_130801.2:c.1314T>C\\\",\\\"NM_130802.2:c.1314T>C\\\",\\\"NM_130803.2:c.1314T>C\\\"]\", \"go.molecular_function\": \"[\\\"four-way junction DNA binding\\\",\\\"Y-form DNA binding\\\",\\\"chromatin binding\\\",\\\"double-stranded DNA binding\\\",\\\"protein binding\\\",\\\"histone-lysine N-methyltransferase activity\\\",\\\"protein binding, bridging\\\",\\\"transcription regulatory region DNA binding\\\",\\\"protein N-terminus binding\\\",\\\"R-SMAD binding\\\"]\", \"gene.full_name\": \"menin 1\", \"vaf\": \"0.996865203762\", \"intervar.evidence_\": \"BA1:1 BS1:1 BP4:1 BP6:1 BP7:1\", \"hgvsp\": \"[\\\"p.His438=\\\",\\\"p.His438=\\\",\\\"\\\",\\\"p.His475=\\\",\\\"p.His433=\\\",\\\"p.His433=\\\",\\\"p.His433=\\\",\\\"p.His398=\\\",\\\"p.His398=\\\",\\\"\\\",\\\"p.His433=\\\",\\\"p.His438=\\\",\\\"p.His438=\\\",\\\"p.His438=\\\",\\\"p.His438=\\\"]\", \"1000g\": \"0.976038\", \"essential_gene\": \"E\", \"gnomad.genome.eas\": \"1\", \"so_term\": \"[\\\"synonymous_variant\\\"]\", \"gene.refgene\": \"MEN1\", \"gnomad.exome.all\": \"0.9944\", \"analysis\": \"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\", \"tags\": \"[\\\"all\\\"]\", \"krg_db_1100\": \"0.998182\", \"insilico_sanger\": \"Y\", \"esp6500.all\": \"0.9761\", \"hgmd.hgvsp\": \"[\\\"p.His433=\\\"]\", \"effect_level\": \"LOW\", \"clinvar.clndbn\": \"[\\\"Multiple_endocrine_neoplasia,_type_1\\\",\\\"not_specified\\\"]\", \"pos\": \"64572557\", \"go.cellular_component\": \"[\\\"nuclear chromosome, telomeric region\\\",\\\"chromatin\\\",\\\"nuclear chromatin\\\",\\\"nucleus\\\",\\\"nucleoplasm\\\",\\\"cytoplasm\\\",\\\"endoplasmic reticulum lumen\\\",\\\"cytosol\\\",\\\"nuclear matrix\\\",\\\"cleavage furrow\\\",\\\"histone methyltransferase complex\\\",\\\"protein complex\\\"]\", \"hgmd.hgvsc\": \"[\\\"NM_130799.2:c.1299T>C\\\"]\", \"gnomad.exome.eas\": \"0.9999\", \"go.biological_process\": \"[\\\"negative regulation of transcription from RNA polymerase II promoter\\\",\\\"MAPK cascade\\\",\\\"mitotic cell cycle\\\",\\\"negative regulation of protein phosphorylation\\\",\\\"osteoblast development\\\",\\\"type B pancreatic cell differentiation\\\",\\\"DNA repair\\\",\\\"transcription, DNA-templated\\\",\\\"cellular response to DNA damage stimulus\\\",\\\"brain development\\\",\\\"negative regulation of cell proliferation\\\",\\\"response to UV\\\",\\\"response to gamma radiation\\\",\\\"negative regulation of cell-substrate adhesion\\\",\\\"positive regulation of transforming growth factor beta receptor signaling pathway\\\",\\\"positive regulation of protein binding\\\",\\\"regulation of activin receptor signaling pathway\\\",\\\"histone lysine methylation\\\",\\\"negative regulation of sequence-specific DNA binding transcription factor activity\\\",\\\"post-translational protein modification\\\",\\\"cellular protein metabolic process\\\",\\\"negative regulation of osteoblast differentiation\\\",\\\"negative regulation of cyclin-dependent protein serine/threonine kinase activity\\\",\\\"negative regulation of cell cycle\\\",\\\"negative regulation of transcription, DNA-templated\\\",\\\"positive regulation of transcription from RNA polymerase II promoter\\\",\\\"negative regulation of JNK cascade\\\",\\\"decidualization\\\",\\\"negative regulation of epithelial cell proliferation\\\",\\\"negative regulation of telomerase activity\\\",\\\"regulation of type B pancreatic cell proliferation\\\",\\\"cellular response to glucose stimulus\\\",\\\"cellular response to peptide hormone stimulus\\\",\\\"response to transforming growth factor beta\\\",\\\"negative regulation of cell cycle G1/S phase transition\\\",\\\"beta-catenin-TCF complex assembly\\\"]\", \"clinvar.id\": \"167288\", \"mim.disease\": \"Angiofibroma, somatic (3) | Adrenal adenoma, somatic (3) | Parathyroid adenoma, somatic (3) | Lipoma, somatic (3) | Carcinoid tumor of lung (3) | Multiple endocrine neoplasia 1, 131100 (3), Autosomal dominant\", \"sample\": \"21Cancer058_MEN1-03_20210622-171-5329\", \"disease_description\": \"DISEASE: Note=MEN1 inactivating mutations are responsible for hyperfunctioning of the parathyroid glands and subsequent primary hyperparathyroidism. Primary hyperparathyroidism can occur in isolation or in association with multiple endocrine neoplasia. {ECO:0000269|PubMed:10634381, ECO:0000269|PubMed:10664521, ECO:0000269|PubMed:12016470, ECO:0000269|PubMed:12699448, ECO:0000269|PubMed:9792884, ECO:0000269|PubMed:9843042, ECO:0000269|PubMed:9888389}.;\", \"filter\": \"PASS\", \"gnomad.genome.all\": \"0.9768\", \"depth\": \"319\", \"qual\": \"9900.77\", \"snv\": \"hg19:11:064572557:A:G\", \"trait_association(gwas)\": \"Urate levels[21768215];\", \"function_description\": \"FUNCTION: Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair. {ECO:0000250, ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12837246, ECO:0000269|PubMed:12874027, ECO:0000269|PubMed:14992727}.;\", \"reference\": \"hg19\", \"ref\": \"A\", \"dbsnp\": \"rs540012\", \"exac.all\": \"0.9927\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"G\", \"spliceai_ds_max\": \"0.07\", \"p(hi)\": \"0.51278\", \"genotype\": \"1/1\", \"clinvar.updated_class\": \"Benign\", \"mim.phenotype_id\": \"[\\\"131100\\\"]\", \"strand\": \"false\", \"mgi_mouse.gene\": \"Men1\", \"clinvar.class\": \"Benign\", \"cancer2770_freq\": \"0.99097\", \"mgi_mouse.phenotype\": \"homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; embryo phenotype; liver/biliary system phenotype; immune system phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (characteristics involving the ability of an organism to live and age normally throughout development and life span); reproductive system phenotype; neoplasm;\", \"exon_in_hgmd\": \"[\\\"9/10\\\"]\", \"chrom\": \"chr11\", \"codon\": \"caC/caC\", \"mim.inheritance\": \"[\\\"AD\\\"]\", \"create_at\": \"2021-12-01T13:39:48.772\", \"exon\": \"[\\\"10/11\\\",\\\"9/10\\\",\\\"\\\",\\\"10/11\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\",\\\"9/10\\\"]\"}"
    val S061BV3 = "{\"hgmd.mut\": \"REF\", \"gerp++.rs\": \"3.35\", \"intervar_\": \"Benign\", \"siphy_29way_logodds\": \"5.500\", \"hgvsc\": \"[\\\"NM_130804.2:c.1636A>G\\\",\\\"NM_000244.3:c.1636A>G\\\",\\\"\\\",\\\"NM_001370251.1:c.1747A>G\\\",\\\"NM_001370259.1:c.1621A>G\\\",\\\"NM_001370260.1:c.1621A>G\\\",\\\"NM_001370261.1:c.1621A>G\\\",\\\"NM_001370262.1:c.1516A>G\\\",\\\"NM_001370263.1:c.1516A>G\\\",\\\"\\\",\\\"NM_130799.2:c.1621A>G\\\",\\\"NM_130800.2:c.1636A>G\\\",\\\"NM_130801.2:c.1636A>G\\\",\\\"NM_130802.2:c.1636A>G\\\",\\\"NM_130803.2:c.1636A>G\\\"]\", \"go.molecular_function\": \"[\\\"four-way junction DNA binding\\\",\\\"Y-form DNA binding\\\",\\\"chromatin binding\\\",\\\"double-stranded DNA binding\\\",\\\"protein binding\\\",\\\"histone-lysine N-methyltransferase activity\\\",\\\"protein binding, bridging\\\",\\\"transcription regulatory region DNA binding\\\",\\\"protein N-terminus binding\\\",\\\"R-SMAD binding\\\"]\", \"cadd.raw\": \"-0.869\", \"gene.full_name\": \"menin 1\", \"vaf\": \"0.996323529412\", \"intervar.evidence_\": \"BA1:1 BS1:1 BP6:1\", \"hgvsp\": \"[\\\"p.Ala546=\\\",\\\"p.Ala546=\\\",\\\"\\\",\\\"p.Ala583=\\\",\\\"p.Ala541=\\\",\\\"p.Ala541=\\\",\\\"p.Ala541=\\\",\\\"p.Ala506=\\\",\\\"p.Ala506=\\\",\\\"\\\",\\\"p.Ala541=\\\",\\\"p.Ala546=\\\",\\\"p.Ala546=\\\",\\\"p.Ala546=\\\",\\\"p.Ala546=\\\"]\", \"provean.score\": \"-0.69\", \"1000g\": \"0.834465\", \"phylop20way_mammalian\": \"0.016\", \"essential_gene\": \"E\", \"gnomad.genome.eas\": \"0.6936\", \"so_term\": \"[\\\"synonymous_variant\\\"]\", \"gene.refgene\": \"MEN1\", \"gnomad.exome.all\": \"0.9390\", \"lrt.score\": \"0.231\", \"analysis\": \"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer058:003\", \"dann.score\": \"0.541\", \"tags\": \"[\\\"all\\\"]\", \"hgmd.tag\": \"DFP\", \"metasvm.pred\": \"T\", \"krg_db_1100\": \"0.731818\", \"hgmd.pmid\": \"18775714\", \"insilico_sanger\": \"Y\", \"esp6500.all\": \"0.9084\", \"hgmd.hgvsp\": \"[\\\"p.Ala541=\\\"]\", \"effect_level\": \"LOW\", \"clinvar.clndbn\": \"[\\\"Multiple_endocrine_neoplasia,_type_1\\\",\\\"not_specified\\\"]\", \"metasvm.score\": \"-0.936\", \"fathmm.pred\": \"D\", \"pos\": \"64572018\", \"lrt.pred\": \"N\", \"go.cellular_component\": \"[\\\"nuclear chromosome, telomeric region\\\",\\\"chromatin\\\",\\\"nuclear chromatin\\\",\\\"nucleus\\\",\\\"nucleoplasm\\\",\\\"cytoplasm\\\",\\\"endoplasmic reticulum lumen\\\",\\\"cytosol\\\",\\\"nuclear matrix\\\",\\\"cleavage furrow\\\",\\\"histone methyltransferase complex\\\",\\\"protein complex\\\"]\", \"hgmd.hgvsc\": \"[\\\"NM_130799.2:c.1621A>G\\\"]\", \"gnomad.exome.eas\": \"0.6980\", \"fathmm.score\": \"-5.71\", \"go.biological_process\": \"[\\\"negative regulation of transcription from RNA polymerase II promoter\\\",\\\"MAPK cascade\\\",\\\"mitotic cell cycle\\\",\\\"negative regulation of protein phosphorylation\\\",\\\"osteoblast development\\\",\\\"type B pancreatic cell differentiation\\\",\\\"DNA repair\\\",\\\"transcription, DNA-templated\\\",\\\"cellular response to DNA damage stimulus\\\",\\\"brain development\\\",\\\"negative regulation of cell proliferation\\\",\\\"response to UV\\\",\\\"response to gamma radiation\\\",\\\"negative regulation of cell-substrate adhesion\\\",\\\"positive regulation of transforming growth factor beta receptor signaling pathway\\\",\\\"positive regulation of protein binding\\\",\\\"regulation of activin receptor signaling pathway\\\",\\\"histone lysine methylation\\\",\\\"negative regulation of sequence-specific DNA binding transcription factor activity\\\",\\\"post-translational protein modification\\\",\\\"cellular protein metabolic process\\\",\\\"negative regulation of osteoblast differentiation\\\",\\\"negative regulation of cyclin-dependent protein serine/threonine kinase activity\\\",\\\"negative regulation of cell cycle\\\",\\\"negative regulation of transcription, DNA-templated\\\",\\\"positive regulation of transcription from RNA polymerase II promoter\\\",\\\"negative regulation of JNK cascade\\\",\\\"decidualization\\\",\\\"negative regulation of epithelial cell proliferation\\\",\\\"negative regulation of telomerase activity\\\",\\\"regulation of type B pancreatic cell proliferation\\\",\\\"cellular response to glucose stimulus\\\",\\\"cellular response to peptide hormone stimulus\\\",\\\"response to transforming growth factor beta\\\",\\\"negative regulation of cell cycle G1/S phase transition\\\",\\\"beta-catenin-TCF complex assembly\\\"]\", \"clinvar.id\": \"134640\", \"mim.disease\": \"Angiofibroma, somatic (3) | Adrenal adenoma, somatic (3) | Parathyroid adenoma, somatic (3) | Lipoma, somatic (3) | Carcinoid tumor of lung (3) | Multiple endocrine neoplasia 1, 131100 (3), Autosomal dominant\", \"hgmd.web.tag\": \"DFP\", \"sample\": \"21Cancer058_MEN1-03_20210622-171-5329\", \"disease_description\": \"DISEASE: Note=MEN1 inactivating mutations are responsible for hyperfunctioning of the parathyroid glands and subsequent primary hyperparathyroidism. Primary hyperparathyroidism can occur in isolation or in association with multiple endocrine neoplasia. {ECO:0000269|PubMed:10634381, ECO:0000269|PubMed:10664521, ECO:0000269|PubMed:12016470, ECO:0000269|PubMed:12699448, ECO:0000269|PubMed:9792884, ECO:0000269|PubMed:9843042, ECO:0000269|PubMed:9888389}.;\", \"filter\": \"PASS\", \"gnomad.genome.all\": \"0.8934\", \"depth\": \"272\", \"qual\": \"8435.77\", \"snv\": \"hg19:11:064572018:T:C\", \"trait_association(gwas)\": \"Urate levels[21768215];\", \"function_description\": \"FUNCTION: Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair. {ECO:0000250, ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12837246, ECO:0000269|PubMed:12874027, ECO:0000269|PubMed:14992727}.;\", \"mutationtaster.pred\": \"P\", \"polyphen2.hvar.score\": \"0.0\", \"fathmm-mkl_coding.pred\": \"N\", \"reference\": \"hg19\", \"vest3_score\": \"0.011\", \"ref\": \"T\", \"phastcons20way_mammalian\": \"0.004\", \"gerp++.gt2\": \"3.35\", \"dbsnp\": \"rs2959656\", \"exac.all\": \"0.9378\", \"mutationtaster.score\": \"1\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"alt\": \"C\", \"cadd.pred\": \"0.030\", \"sift.pred\": \"T\", \"spliceai_ds_max\": \"0\", \"mutationassessor.pred\": \"N\", \"polyphen2.hdiv.score\": \"0.0\", \"p(hi)\": \"0.51278\", \"genotype\": \"1/1\", \"clinvar.updated_class\": \"Benign\", \"metalr.score\": \"0.000\", \"hgmd.web.literature\": \"{1. Bazzi (2008) Gastroenterology 135: 1698 PubMed: 18775714 MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells. | Primary literature report | fp:original reference supporting inclusion | No comments},{2. Shimazu (2011) Cancer Sci 102: 2097 PubMed: 21819486 Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. | Functional characterisation | . | ~80% stability of wild-type.},{3. Belar (2012) Clin Endocrinol (Oxf) 76: 719 PubMed: 22026581 Novel mutations in MEN1 CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. | Additional phenotype | fp:additional reference supporting inclusion | Multiple endocrine neoplasia 1},{4. Johnston (2012) Am J Hum Genet 91: 97 PubMed: 22703879 Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. | Additional literature report | dmq:additional reference not conclusive | found in 385/387 individuals},{5. Bodian (2014) PLoS One 9: e94554 PubMed: 24728327 Germline variation in cancer-susceptibility genes in a healthy ancestrally diverse cohort: implications for individual genome sequencing. | Additional literature report | dm:additional reference not supporting inclusion | found in healthy ancestrally diverse cohort. Table S1.},{6. Nozières (2014) Ann Endocrinol (Paris) 75: 133 PubMed: 24997771 p.Ala541Thr variant of MEN1 gene: A non deleterious polymorphism or a pathogenic mutation? | Functional characterisation | fp:additional reference supporting inclusion | Overexpression does not inhibit cell growth (unlike wild-type).},{7. Liu (2015) Oncol Lett 9: 1177 PubMed: 25663877 Genetic analysis of a patient with coexisting acromegaly thyroid papillary carcinoma and subcutaneous fibroma. | Additional phenotype | dmq:additional reference not conclusive | Pituitary and thyroid carcinoma ?},{8. Maxwell (2016) Am J Hum Genet 98: 801 PubMed: 27153395 Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. | Additional literature report | dm:additional reference not supporting inclusion | Table S5. Final call Benign.}\", \"mutationassessor.score\": \"-0.69\", \"polyphen2.hdiv.pred\": \"B\", \"mim.phenotype_id\": \"[\\\"131100\\\"]\", \"strand\": \"false\", \"sift.score\": \"0.866\", \"mgi_mouse.gene\": \"Men1\", \"polyphen2.hvar.pred\": \"B\", \"fathmm-mkl_coding.score\": \"0.006\", \"provean.pred\": \"N\", \"clinvar.class\": \"Benign\", \"cancer2770_freq\": \"0.72834\", \"mgi_mouse.phenotype\": \"homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; embryo phenotype; liver/biliary system phenotype; immune system phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (characteristics involving the ability of an organism to live and age normally throughout development and life span); reproductive system phenotype; neoplasm;\", \"exon_in_hgmd\": \"[\\\"10/10\\\"]\", \"chrom\": \"chr11\", \"codon\": \"Gca/Gca\", \"metalr.pred\": \"T\", \"mim.inheritance\": \"[\\\"AD\\\"]\", \"create_at\": \"2021-12-01T13:39:48.772\", \"exon\": \"[\\\"11/11\\\",\\\"10/10\\\",\\\"\\\",\\\"11/11\\\",\\\"10/10\\\",\\\"10/10\\\",\\\"10/10\\\",\\\"10/10\\\",\\\"10/10\\\",\\\"\\\",\\\"10/10\\\",\\\"10/10\\\",\\\"10/10\\\",\\\"10/10\\\",\\\"10/10\\\"]\"}"
    val S030NEGATIVEADD = "{ \"ge_green\": \"Severe Paediatric Disorders | Severe Paediatric Disorders | Inherited bleeding disorders | Bleeding and platelet disorders | Inherited bleeding disorders\", \"hgvsc\": \"[\\\"NM_001312674.2:c.1113C>G\\\",\\\"NM_000504.4:c.1245C>G\\\",\\\"NM_001312675.2:c.*236C>G\\\"]\", \"reference\": \"hg19\", \"ref\": \"C\", \"cadd.raw\": \"4.022809\", \"vaf\": \"0.406451612903\", \"mutationtaster.score\": \"1&1&1\", \"class_order\": \"50\", \"hgvsp\": \"[\\\"p.Cys371Trp\\\",\\\"p.Cys415Trp\\\",\\\"p.?\\\"]\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"alt\": \"G\", \"cadd.pred\": \"26.5\", \"sift.pred\": \"deleterious\", \"gene.refgene\": \"F10\", \"spliceai_ds_max\": \"0.0\", \"lrt.score\": \"0.000000\", \"analysis\": \"01db4ff4-9689-47b0-b0d9-1659788912c5:22AN003:007\", \"gnomad.total\": \"0\", \"tags\": \"[\\\"candidate\\\",\\\"all\\\"]\", \"genotype\": \"0/1\", \"intervar.class\": \"Uncertain_significance\", \"intervar.evidence.pv\": \"PM1&PM2\", \"polyphen.pred\": \"probably_damaging\", \"insilico_sanger\": \"Y\", \"polyphen.score\": \"1\", \"hgmd.hgvsp\": \"[\\\"p.Cys415Trp\\\"]\", \"effect_level\": \"MED\", \"fathmm.pred\": \"D\", \"strand\": \"true\", \"sift.score\": \"0\", \"pos\": \"113803609\", \"lrt.pred\": \"D\", \"hgmd.hgvsc\": \"[\\\"NM_000504.4:c.1245C>G\\\"]\", \"class\": \"MAF0\", \"fathmm.score\": \"-4.0\", \"mim.disease\": \"Factor X deficiency, 227600 (3), Autosomal recessive\", \"ge_class\": \"Green\", \"exon_in_hgmd\": \"[\\\"8/8\\\"]\", \"sample\": \"22AN003_20220801-171-5110_F8-07_I\", \"disease_description\": \"DISEASE: Factor X deficiency (FA10D) [MIM:227600]: A hemorrhagic disease with variable presentation. Affected individuals can manifest prolonged nasal and mucosal hemorrhage, menorrhagia, hematuria, and occasionally hemarthrosis. Some patients do not have clinical bleeding diathesis. {ECO:0000269|PubMed:10468877, ECO:0000269|PubMed:10739379, ECO:0000269|PubMed:10746568, ECO:0000269|PubMed:11248282, ECO:0000269|PubMed:11728527, ECO:0000269|PubMed:12574802, ECO:0000269|PubMed:12945883, ECO:0000269|PubMed:15075089, ECO:0000269|PubMed:15650540, ECO:0000269|PubMed:17393015, ECO:0000269|PubMed:19135706, ECO:0000269|PubMed:1973167, ECO:0000269|PubMed:1985698, ECO:0000269|PubMed:25313940, ECO:0000269|PubMed:26222694, ECO:0000269|PubMed:2790181, ECO:0000269|PubMed:7669671, ECO:0000269|PubMed:7860069, ECO:0000269|PubMed:8529633, ECO:0000269|PubMed:8845463, ECO:0000269|PubMed:8910490}. Note=The disease is caused by mutations affecting the gene represented in this entry.; \", \"chrom\": \"chr13\", \"filter\": \"PASS\", \"codon\": \"tgC/tgG\", \"mim.inheritance\": \"[\\\"AR\\\"]\", \"depth\": \"310\", \"qual\": \"2680.64\", \"snv\": \"hg19:13:113803609:C:G\", \"create_at\": \"2022-08-05T05:32:50.005\", \"exon\": \"[\\\"7/7\\\",\\\"8/8\\\",\\\"8/8\\\"]\", \"function_description\": \"FUNCTION: Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.; \", \"mutationtaster.pred\": \"D&D&D\" }"
    val S061POSITIVE = "{\"hgmd.mut\": \"ALT\", \"gerp++.rs\": \"4.24\", \"polyphen2.hvar.score\": \"1.0\", \"intervar_\": \"Uncertain significance\", \"fathmm-mkl_coding.pred\": \"D\", \"siphy_29way_logodds\": \"14.501\", \"hgvsc\": \"[\\\"NM_130804.2:c.845C>A\\\",\\\"NM_000244.3:c.845C>A\\\",\\\"\\\",\\\"NM_001370251.1:c.830C>A\\\",\\\"NM_001370259.1:c.830C>A\\\",\\\"NM_001370260.1:c.830C>A\\\",\\\"NM_001370261.1:c.830C>A\\\",\\\"NM_001370262.1:c.725C>A\\\",\\\"NM_001370263.1:c.725C>A\\\",\\\"\\\",\\\"NM_130799.2:c.830C>A\\\",\\\"NM_130800.2:c.845C>A\\\",\\\"NM_130801.2:c.845C>A\\\",\\\"NM_130802.2:c.845C>A\\\",\\\"NM_130803.2:c.845C>A\\\"]\", \"reference\": \"hg19\", \"go.molecular_function\": \"[\\\"four-way junction DNA binding\\\",\\\"Y-form DNA binding\\\",\\\"chromatin binding\\\",\\\"double-stranded DNA binding\\\",\\\"protein binding\\\",\\\"histone-lysine N-methyltransferase activity\\\",\\\"protein binding, bridging\\\",\\\"transcription regulatory region DNA binding\\\",\\\"protein N-terminus binding\\\",\\\"R-SMAD binding\\\"]\", \"vest3_score\": \"0.967\", \"ref\": \"G\", \"phastcons20way_mammalian\": \"0.992\", \"gerp++.gt2\": \"4.24\", \"cadd.raw\": \"5.847\", \"gene.full_name\": \"menin 1\", \"vaf\": \"0.476377952756\", \"intervar.evidence_\": \"PM2:1 PP3:1\", \"mutationtaster.score\": \"1\", \"hgvsp\": \"[\\\"p.Pro282His\\\",\\\"p.Pro282His\\\",\\\"\\\",\\\"p.Pro277His\\\",\\\"p.Pro277His\\\",\\\"p.Pro277His\\\",\\\"p.Pro277His\\\",\\\"p.Pro242His\\\",\\\"p.Pro242His\\\",\\\"\\\",\\\"p.Pro277His\\\",\\\"p.Pro282His\\\",\\\"p.Pro282His\\\",\\\"p.Pro282His\\\",\\\"p.Pro282His\\\"]\", \"provean.score\": \"-8.35\", \"phylop20way_mammalian\": \"0.949\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"essential_gene\": \"E\", \"so_term\": \"[\\\"missense_variant\\\"]\", \"alt\": \"T\", \"cadd.pred\": \"27.3\", \"sift.pred\": \"D\", \"gene.refgene\": \"MEN1\", \"spliceai_ds_max\": \"0.06\", \"mutationassessor.pred\": \"M\", \"lrt.score\": \"0.000\", \"polyphen2.hdiv.score\": \"1\", \"analysis\": \"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004\", \"dann.score\": \"0.996\", \"p(hi)\": \"0.51278\", \"tags\": \"[\\\"all\\\",\\\"candidate\\\"]\", \"genotype\": \"0/1\", \"clinvar.updated_class\": \"Conflicting interpretations of pathogenicity\", \"metalr.score\": \"0.987\", \"hgmd.tag\": \"DM\", \"metasvm.pred\": \"D\", \"krg_db_1100\": \"0\", \"hgmd.pmid\": \"12016470\", \"insilico_sanger\": \"Y\", \"hgmd.hgvsp\": \"[\\\"p.Pro277His\\\"]\", \"hgmd.web.literature\": \"{1. Perrier (2002) World J Surg 26: 907 PubMed: 12016470 Genetic screening for MEN1 mutations in families presenting with familial primary hyperparathyroidism. | Primary literature report | dm:original reference supporting inclusion | No comments},{2. Shimazu (2011) Cancer Sci 102: 2097 PubMed: 21819486 Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. | Functional characterisation | dm:additional reference supporting inclusion | ~20% stability of wild-type.}\", \"mutationassessor.score\": \"2.66\", \"effect_level\": \"MED\", \"clinvar.clndbn\": \"[\\\"Multiple_endocrine_neoplasia,_type_1\\\",\\\"Hereditary_cancer-predisposing_syndrome\\\"]\", \"metasvm.score\": \"0.997\", \"polyphen2.hdiv.pred\": \"D\", \"mim.phenotype_id\": \"[\\\"131100\\\"]\", \"fathmm.pred\": \"D\", \"strand\": \"false\", \"sift.score\": \"0\", \"pos\": \"64574565\", \"lrt.pred\": \"D\", \"mgi_mouse.gene\": \"Men1\", \"go.cellular_component\": \"[\\\"nuclear chromosome, telomeric region\\\",\\\"chromatin\\\",\\\"nuclear chromatin\\\",\\\"nucleus\\\",\\\"nucleoplasm\\\",\\\"cytoplasm\\\",\\\"endoplasmic reticulum lumen\\\",\\\"cytosol\\\",\\\"nuclear matrix\\\",\\\"cleavage furrow\\\",\\\"histone methyltransferase complex\\\",\\\"protein complex\\\"]\", \"m-cap.score\": \"0.530\", \"hgmd.hgvsc\": \"[\\\"NM_130799.2:c.830C>A\\\"]\", \"polyphen2.hvar.pred\": \"D\", \"fathmm-mkl_coding.score\": \"0.985\", \"fathmm.score\": \"-6.63\", \"provean.pred\": \"D\", \"go.biological_process\": \"[\\\"negative regulation of transcription from RNA polymerase II promoter\\\",\\\"MAPK cascade\\\",\\\"mitotic cell cycle\\\",\\\"negative regulation of protein phosphorylation\\\",\\\"osteoblast development\\\",\\\"type B pancreatic cell differentiation\\\",\\\"DNA repair\\\",\\\"transcription, DNA-templated\\\",\\\"cellular response to DNA damage stimulus\\\",\\\"brain development\\\",\\\"negative regulation of cell proliferation\\\",\\\"response to UV\\\",\\\"response to gamma radiation\\\",\\\"negative regulation of cell-substrate adhesion\\\",\\\"positive regulation of transforming growth factor beta receptor signaling pathway\\\",\\\"positive regulation of protein binding\\\",\\\"regulation of activin receptor signaling pathway\\\",\\\"histone lysine methylation\\\",\\\"negative regulation of sequence-specific DNA binding transcription factor activity\\\",\\\"post-translational protein modification\\\",\\\"cellular protein metabolic process\\\",\\\"negative regulation of osteoblast differentiation\\\",\\\"negative regulation of cyclin-dependent protein serine/threonine kinase activity\\\",\\\"negative regulation of cell cycle\\\",\\\"negative regulation of transcription, DNA-templated\\\",\\\"positive regulation of transcription from RNA polymerase II promoter\\\",\\\"negative regulation of JNK cascade\\\",\\\"decidualization\\\",\\\"negative regulation of epithelial cell proliferation\\\",\\\"negative regulation of telomerase activity\\\",\\\"regulation of type B pancreatic cell proliferation\\\",\\\"cellular response to glucose stimulus\\\",\\\"cellular response to peptide hormone stimulus\\\",\\\"response to transforming growth factor beta\\\",\\\"negative regulation of cell cycle G1/S phase transition\\\",\\\"beta-catenin-TCF complex assembly\\\"]\", \"clinvar.class\": \"Conflicting_interpretations_of_pathogenicity|Likely_pathogenic(1),Uncertain_significance(1)\", \"cancer2770_freq\": \"0\", \"m-cap.pred\": \"D\", \"clinvar.id\": \"403801\", \"mim.disease\": \"Angiofibroma, somatic (3) | Adrenal adenoma, somatic (3) | Parathyroid adenoma, somatic (3) | Lipoma, somatic (3) | Carcinoid tumor of lung (3) | Multiple endocrine neoplasia 1, 131100 (3), Autosomal dominant\", \"hgmd.web.tag\": \"DM\", \"mgi_mouse.phenotype\": \"homeostasis/metabolism phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; embryo phenotype; liver/biliary system phenotype; immune system phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (characteristics involving the ability of an organism to live and age normally throughout development and life span); reproductive system phenotype; neoplasm;\", \"exon_in_hgmd\": \"[\\\"6/10\\\"]\", \"sample\": \"21Cancer083_MEN1-04_20210901-171-5037\", \"disease_description\": \"DISEASE: Note=MEN1 inactivating mutations are responsible for hyperfunctioning of the parathyroid glands and subsequent primary hyperparathyroidism. Primary hyperparathyroidism can occur in isolation or in association with multiple endocrine neoplasia. {ECO:0000269|PubMed:10634381, ECO:0000269|PubMed:10664521, ECO:0000269|PubMed:12016470, ECO:0000269|PubMed:12699448, ECO:0000269|PubMed:9792884, ECO:0000269|PubMed:9843042, ECO:0000269|PubMed:9888389}.;\", \"chrom\": \"chr11\", \"filter\": \"PASS\", \"codon\": \"cCc/cAc\", \"metalr.pred\": \"D\", \"mim.inheritance\": \"[\\\"AD\\\"]\", \"depth\": \"254\", \"qual\": \"2932.77\", \"snv\": \"hg19:11:064574565:G:T\", \"create_at\": \"2021-12-02T14:09:31.433\", \"exon\": \"[\\\"7/11\\\",\\\"6/10\\\",\\\"\\\",\\\"6/11\\\",\\\"6/10\\\",\\\"6/10\\\",\\\"6/10\\\",\\\"6/10\\\",\\\"6/10\\\",\\\"\\\",\\\"6/10\\\",\\\"6/10\\\",\\\"6/10\\\",\\\"6/10\\\",\\\"6/10\\\"]\", \"trait_association(gwas)\": \"Urate levels[21768215];\", \"function_description\": \"FUNCTION: Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity). May be involved in DNA repair. {ECO:0000250, ECO:0000269|PubMed:11274402, ECO:0000269|PubMed:11526476, ECO:0000269|PubMed:12837246, ECO:0000269|PubMed:12874027, ECO:0000269|PubMed:14992727}.;\", \"mutationtaster.pred\": \"D\", \"class_order\": \"32\", \"class\": \"HGMD_DM\"}"
    val S061POSITIVEADD = "{\"hgmd.mut\": \"ALT\", \"hgvsc\": \"[\\\"NM_001351834.2:c.8283_8284del\\\",\\\"NM_000051.3:c.8283_8284del\\\",\\\"NM_001330368.2:c.641-34161_641-34160del\\\",\\\"NM_001351110.2:c.695-7940_695-7939del\\\",\\\"NR_147053.2:n.2302-7940_2302-7939del\\\"]\", \"reference\": \"hg19\", \"go.molecular_function\": \"[\\\"DNA binding\\\",\\\"protein serine/threonine kinase activity\\\",\\\"DNA-dependent protein kinase activity\\\",\\\"protein binding\\\",\\\"ATP binding\\\",\\\"1-phosphatidylinositol-3-kinase activity\\\",\\\"protein complex binding\\\",\\\"protein dimerization activity\\\",\\\"protein N-terminus binding\\\"]\", \"ref\": \"CCT\", \"gene.full_name\": \"ATM serine/threonine kinase\", \"vaf\": \"0.528901734104\", \"hgvsp\": \"[\\\"p.Gln2762AlafsTer6\\\",\\\"p.Gln2762AlafsTer6\\\",\\\"\\\",\\\"\\\",\\\"\\\"]\", \"splicing_distance\": \"0\", \"organism\": \"homo sapiens\", \"essential_gene\": \"N\", \"so_term\": \"[\\\"frameshift_variant\\\"]\", \"alt\": \"C\", \"gene.refgene\": \"ATM\", \"spliceai_ds_max\": \"0.06\", \"analysis\": \"025394fd-39ec-4cdf-9398-f62959aacdf5:21Cancer083:004\", \"p(hi)\": \"0.17033\", \"tags\": \"[\\\"all\\\",\\\"candidate\\\"]\", \"genotype\": \"0/1\", \"hgmd.tag\": \"DM\", \"known_rec_info\": \"recessive\", \"krg_db_1100\": \"0\", \"hgmd.pmid\": \"8845835\", \"insilico_sanger\": \"Y\", \"hgmd.hgvsp\": \"[\\\"p.Gln2762AlafsTer6\\\"]\", \"hgmd.web.literature\": \"{1. Gilad (1996) Hum Mol Genet 5: 433 PubMed: 8845835 Predominance of null mutations in ataxia-telangiectasia. | Primary literature report | dm:original reference supporting inclusion | No comments}\", \"effect_level\": \"HIGH\", \"clinvar.clndbn\": \"[\\\"Hereditary_cancer-predisposing_syndrome\\\"]\", \"mim.phenotype_id\": \"[\\\"208900\\\"]\", \"strand\": \"false\", \"pos\": \"108213957\", \"mgi_mouse.gene\": \"Atm\", \"go.cellular_component\": \"[\\\"chromosome, telomeric region\\\",\\\"nuclear chromosome, telomeric region\\\",\\\"nucleus\\\",\\\"nucleoplasm\\\",\\\"nucleolus\\\",\\\"spindle\\\",\\\"cytoplasmic vesicle\\\",\\\"DNA repair complex\\\"]\", \"p(rec)\": \"0.15782\", \"hgmd.hgvsc\": \"[\\\"NM_000051.3:c.8283_8284del\\\"]\", \"go.biological_process\": \"[\\\"double-strand break repair via homologous recombination\\\",\\\"DNA double-strand break processing\\\",\\\"DNA synthesis involved in DNA repair\\\",\\\"strand displacement\\\",\\\"ovarian follicle development\\\",\\\"response to hypoxia\\\",\\\"somitogenesis\\\",\\\"pre-B cell allelic exclusion\\\",\\\"immunoglobulin production\\\",\\\"DNA replication\\\",\\\"DNA repair\\\",\\\"double-strand break repair via nonhomologous end joining\\\",\\\"protein phosphorylation\\\",\\\"cellular response to DNA damage stimulus\\\",\\\"DNA damage induced protein phosphorylation\\\",\\\"DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest\\\",\\\"cell cycle arrest\\\",\\\"mitotic spindle assembly checkpoint\\\",\\\"reciprocal meiotic recombination\\\",\\\"male meiotic nuclear division\\\",\\\"female meiotic nuclear division\\\",\\\"signal transduction\\\",\\\"brain development\\\",\\\"heart development\\\",\\\"determination of adult lifespan\\\",\\\"intrinsic apoptotic signaling pathway in response to DNA damage\\\",\\\"post-embryonic development\\\",\\\"response to ionizing radiation\\\",\\\"regulation of autophagy\\\",\\\"peptidyl-serine phosphorylation\\\",\\\"negative regulation of B cell proliferation\\\",\\\"regulation of telomere maintenance via telomerase\\\",\\\"positive regulation of telomere maintenance via telomerase\\\",\\\"positive regulation of histone phosphorylation\\\",\\\"V(D)J recombination\\\",\\\"multicellular organism growth\\\",\\\"phosphatidylinositol-3-phosphate biosynthetic process\\\",\\\"peptidyl-serine autophosphorylation\\\",\\\"lipoprotein catabolic process\\\",\\\"regulation of apoptotic process\\\",\\\"positive regulation of apoptotic process\\\",\\\"positive regulation of DNA damage response, signal transduction by p53 class mediator\\\",\\\"positive regulation of neuron apoptotic process\\\",\\\"meiotic telomere clustering\\\",\\\"protein autophosphorylation\\\",\\\"thymus development\\\",\\\"oocyte development\\\",\\\"neuron apoptotic process\\\",\\\"regulation of telomerase activity\\\",\\\"histone mRNA catabolic process\\\",\\\"cellular response to gamma radiation\\\",\\\"cellular response to X-ray\\\",\\\"cellular response to nitrosative stress\\\",\\\"signal transduction involved in mitotic G2 DNA damage checkpoint\\\",\\\"replicative senescence\\\",\\\"establishment of RNA localization to telomere\\\",\\\"establishment of macromolecular complex localization to telomere\\\",\\\"regulation of cellular response to heat\\\",\\\"regulation of signal transduction by p53 class mediator\\\",\\\"positive regulation of DNA catabolic process\\\",\\\"regulation of microglial cell activation\\\",\\\"negative regulation of TORC1 signaling\\\",\\\"negative regulation of telomere capping\\\",\\\"positive regulation of telomere maintenance via telomere lengthening\\\",\\\"positive regulation of telomerase catalytic core complex assembly\\\",\\\"regulation of cellular response to gamma radiation\\\"]\", \"clinvar.class\": \"Pathogenic\", \"cancer2770_freq\": \"0\", \"clinvar.id\": \"482713\", \"mim.disease\": \"Lymphoma, mantle cell, somatic (3) | Lymphoma, B-cell non-Hodgkin, somatic (3) | Ataxia-telangiectasia, 208900 (3), Autosomal recessive | {Breast cancer, susceptibility to}, 114480 (3), Autosomal dominant, Somatic mutation | T-cell prolymphocytic leukemia, somatic (3)\", \"hgmd.web.tag\": \"DM\", \"mgi_mouse.phenotype\": \"nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (characteristics involving the ability of an organism to live and age normally throughout development and life span); reproductive system phenotype; growth/size/body region phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); neoplasm; endocrine/exocrine gland phenotype; cellular phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands);\", \"exon_in_hgmd\": \"[\\\"57/63\\\"]\", \"sample\": \"21Cancer083_MEN1-04_20210901-171-5037\", \"disease_description\": \"DISEASE: Ataxia telangiectasia (AT) [MIM:208900]: A rare recessive disorder characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. Patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation. {ECO:0000269|PubMed:10234507, ECO:0000269|PubMed:10425038, ECO:0000269|PubMed:10817650, ECO:0000269|PubMed:10873394, ECO:0000269|PubMed:27664052, ECO:0000269|PubMed:7792600, ECO:0000269|PubMed:8589678, ECO:0000269|PubMed:8665503, ECO:0000269|PubMed:8698354, ECO:0000269|PubMed:8755918, ECO:0000269|PubMed:8789452, ECO:0000269|PubMed:8797579, ECO:0000269|PubMed:8808599, ECO:0000269|PubMed:8845835, ECO:0000269|PubMed:9043869, ECO:0000269|PubMed:9150358, ECO:0000269|PubMed:9443866, ECO:0000269|PubMed:9450874, ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9497252, ECO:0000269|PubMed:9521587, ECO:0000269|PubMed:9711876, ECO:0000269|PubMed:9792409, ECO:0000269|PubMed:9792410, ECO:0000269|PubMed:9872980, ECO:0000269|PubMed:9887333}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=Defects in ATM contribute to T-cell acute lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). TPLL is characterized by a high white blood cell count, with a predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, skin lesions and serous effusion. The clinical course is highly aggressive, with poor response to chemotherapy and short survival time. TPLL occurs both in adults as a sporadic disease and in younger AT patients. {ECO:0000269|PubMed:9288106, ECO:0000269|PubMed:9334731, ECO:0000269|PubMed:9463314, ECO:0000269|PubMed:9488043, ECO:0000269|PubMed:9573030}.; DISEASE: Note=Defects in ATM contribute to B-cell non-Hodgkin lymphomas (BNHL), including mantle cell lymphoma (MCL). {ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:10706620, ECO:0000269|PubMed:9288106}.; DISEASE: Note=Defects in ATM contribute to B-cell chronic lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in the elderly. It is characterized by the accumulation of mature CD5+ B-lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure. {ECO:0000269|PubMed:10023947, ECO:0000269|PubMed:10397742, ECO:0000269|PubMed:9892178}.;\", \"chrom\": \"chr11\", \"filter\": \"PASS\", \"codon\": \"CTc/c\", \"mim.inheritance\": \"[\\\"AR\\\",\\\"AD, Somatic mutation\\\"]\", \"depth\": \"346\", \"pathway(kegg)_full\": \"[\\\"Cell cycle\\\",\\\"p53 signaling pathway\\\",\\\"Apoptosis\\\"]\", \"qual\": \"6604.73\", \"snv\": \"hg19:11:108213957:CCT:C\", \"create_at\": \"2021-12-02T14:09:31.434\", \"exon\": \"[\\\"58/64\\\",\\\"57/63\\\",\\\"\\\",\\\"\\\",\\\"\\\"]\", \"trait_association(gwas)\": \"Response to metformin[21845381];Rheumatoid arthritis[24390342;24390342];Melanoma[21983787];Response to metformin in type 2 diabetes (glycemic)[21186350];Gastric adenocarcinoma (histologically verified)[26098866;26098866];Gastric cancer[26098866;26098866];\", \"function_description\": \"FUNCTION: Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates DYRK2, CHEK2, p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends. Phosphorylation of DYRK2 in nucleus in response to genotoxic stress prevents its MDM2-mediated ubiquitination and subsequent proteasome degradation. Phosphorylates ATF2 which stimulates its function in DNA damage response. {ECO:0000269|PubMed:10973490, ECO:0000269|PubMed:12556884, ECO:0000269|PubMed:14871926, ECO:0000269|PubMed:15916964, ECO:0000269|PubMed:16086026, ECO:0000269|PubMed:16858402, ECO:0000269|PubMed:17923702, ECO:0000269|PubMed:19965871}.;\", \"class_order\": \"100\", \"class\": \"High_effect\"}"
}